Document:

U.S. Supply and Distribution Agreement

 Exhibit 10.25 
 Confidential Portions of this Exhibit marked as [**] have been omitted pursuant to a 

request for confidentiality and filed separately with the Securities and Exchange Commission. 

 
 U.S. SUPPLY AND DISTRIBUTION AGREEMENT 

This U.S. Supply and Distribution Agreement (“Agreement”) is entered into this 18th day of April, 2008 (“Execution Date”) by and between:

  

			
		  	 Cobalt Pharmaceuticals Inc.,

a Canadian corporation,
 with offices located
at

		  	6500 Kitimat Road
		  	 Mississauga, ON U5N 2B8

Canada; and

		
		  	Cobalt Laboratories Inc.,
		  	a Delaware corporation,
		  	with offices located at
		  	24840 South Tarniami Trail
		  	Bonita Springs, Florida 34134
		  	 (Cobalt Pharmaceuticals Inc. and Cobalt
 Laboratories Inc. hereinafter are collectively referred
 to as
“COBALT”)

		
	and	  	
		
		  	Pfizer Inc.
		  	a Delaware corporation,
		  	(hereinafter referred to as
		  	 “PFIZER”) with offices located at
 235 East
42
nd Street

		  	New York, New York 10017-5755

 WHEREAS, PFIZER and its Affiliates own the following U.S, Patents relating to
PFIZER’s drug Lipitor®: 4,681,893 (“893 Patent”), 5,273,995 (“995 Patent”), 5,686,104
(“104 Patent”), 5,969,156 (“156 Patent”) and 6,126,971 (“971 Patent”); 
 WHEREAS, COBALT has
filed with the FDA (as defined below) a New Drug Application, No. 22-245, under Section 505(b) (2) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. 355(b)(2) (“Section 505(b)(2)”), requesting approval from the FDA to make
and sell a product containing atorvastatin sodium as its active ingredient; 
 WHEREAS, PFIZER and COBALT
have a dispute about whether COBALT may properly rely on PF1ZER’s NDA for Lipitor® as a basis for approval
of its application to market a sodium salt version of atorvastatin under Section 505(b)(2), which dispute, if PFIZER prevails, would preclude FDA approval for COBALT’s New Drug Application, No. 22-245; 

  

 WHEREAS, PFIZER is a plaintiff in a civil action entitled Pfizer Inc. et. al. v. Cobalt
Pharmaceuticals. Inc., Civil Action No. 07-790-JJF, pending in the United States District Court for the District of Delaware (“Action”), in which PFIZER alleges that COBALT infringed and induced infringement of the ‘995
Patent as specified therein; 
 WHEREAS, COBALT has filed an answer and counterclaims in the Action seeking judgments of
non-infringement and invalidity of the ‘104, ‘156, ‘995, and ‘971 Patents, but not the ‘893 Patent; and 
 WHEREAS, PFIZER and COBALT desire (a) to resolve the Action and seek court approval for a Consent Judgment and Order of Court (as defined below) with respect to the Action, (b) resolve the
dispute over whether COBALT can properly reference PFIZER’s data in its Section 505(b)(2) application, and (c) upon effectiveness of the Consent Judgment and Order of Court, to grant COBALT the right to market, sell and distribute the
Product (as defined below) in the Territory (as defined below) as provided herein. 
 NOW, THEREFORE, in consideration of the
foregoing premises and the covenants exchanged herein and other good and valuable consideration, the sufficiency and receipt of all of which are hereby acknowledged, COBALT and PFIZER intending to be legally bound agree as follows: 

 

	I.	DEFINITIONS 

“Affiliate(s)” shall mean, with respect to any entity, any corporation, association, company, organization or other entity which
directly or indirectly controls, is controlled by or under common control with COBALT or PFIZER, as the case may be. For purposes of this definition, control means the ability, directly or indirectly, through ownership of securities, by agreement,
or by any other method, to direct more than fifty (50%) of the outstanding equity votes of any entity, whether or not represented by securities, or to otherwise control the management decisions of any entity. 

“ANDA” shall mean Abbreviated New Drug Application as defined in 21 CFR § 355(j) et seq., as amended from time to time

 “cGMPs” shall mean Current Good Manufacturing Practices as defined in 21 CFR § 210 at seq., as amended time to
time. 

  
 (2)

 “Calendar Quarter” shall mean those consecutive three (3) calendar month
periods beginning January 1, April 1, July 1, and October 1, respectively. 
 “Canada Supply
Agreement” means the Canada Supply and Distribution Agreement dated as of the date hereof by and between Pfizer Canada Inc, and Cobalt Pharmaceuticals Trio. 

“Commencement Date” shall mean, with respect to any Specific Product, the earlier of
(a) November 30, 2011 or (b) the first date on which all of the following events have occurred; (i) any Third Party receives from the FDA final approval for an ANDA to commercially sell a pharmaceutical product for use in humans
containing atorvastatin calcium as the sole active ingredient, determined by the FDA to be bioequivalent and designated by the FDA to be AB-rated to Lipitor® (the “Generic Product”), and (ii) such Third Party has made the Generic Product available for purchase in commercial quantities (meaning at least 10%
or more availability) to major wholesalers, retail pharmacy chains and managed care providers sufficient to meet a significant portion (at least 10%) of such Third Party’s initial stocking requirements), as mutually determined by the Parties,
in the Territory; it being understood and agreed that in no event will the Commencement Date occur prior to the Effective Date (as defined in Section 2.1 below). 
 “Commercially Reasonable Efforts” shall mean that degree of effort, expertise and resources which a person of ordinary skill, ability and experience in the matters addressed herein would utilize
and otherwise apply with respect to fulfilling the obligations assumed hereunder. 
 “Consent Judgment and Order of
Court” refers to the Consent Judgment and Order of Court attached hereto as Annex 1. 
 “FDA” shall mean the Food
and Drug Administration of the United States of America. 
 “FFDCA” shall mean the Federal Food, Drug and Cosmetic Act,
as amended, 21 U.S.C. §301 et seq,, and any related federal and/or state law or regulation in the Territory pertaining to the safety, effectiveness, adulteration, misbranding, mishandling, packaging, labeling or storage of pharmaceutical
ingredients, finished pharmaceutical products, and/or medical devices that may be applicable to the Products during the Term. 

  
 (3)

 “Intellectual Property” shall mean all intellectual property owned or licensed to
a party including, without limitation, provisional patent applications, utility patent applications, patents, and reissues, reexaminations, extensions and substitutions thereof, trade secrets, know-how, copyrights, trade names, trademarks, and trade
dress. 
 “Law” shall mean any local, state or federal rule, regulation, statute or law. 

“Losses” shall mean any liabilities, damages, costs or expenses, including reasonable attorneys’ fees, incurred by either
Party which arise from any claim, lawsuit or other action by a Third Party. 
 “NDA” means the
PFIZER New Drug Application (NDA 020702) filed with and approved by the FDA relating to Lipitorl) 10mg, 20mg, 40mg and 80mg dosage strengths 
 “Net Sales” shall mean,
with respect to sales of the Products by COBALT or its Authorized Sublicensees (as defined in Section 2.2) or their respective Affiliates to any Third Party, the gross amount invoiced therefor, less the following amounts as and to the extent
consistent in kind and amount with industry practice: 
  

	 	(a)	quantity and/or normal and customary cash discounts allowed or taken; 

  

	 	(b)	freight, postage and insurance related to such sales (to the extent such cost is incurred by COBALT); 

 

	 	(c)	credits, rebates and/or adjustments allowed or given by reason of Products expiration dating, rejections or returns, retroactive price reductions or programs with
wholesalers or other distributors or resellers according to which they are entitled to chargeback rebates, credits or adjustments; 

  

	 	(d)	rebates, administrative fees, reimbursements or similar payments to or for Medicaid or any other government programs (whether mandated or voluntary), hospitals, health
maintenance organizations, insurance carriers, buying groups or other entities in connection with the purchase or utilization of Products; and 

  

	 	(e)	any shipping and transportation costs paid by COBALT in connection with the transportation of the Products from the PFIZER shipping point to COBALT’S facility as
specified in section 5,1, including, without limitation, any duty, tax, fee or other assessment imposed by any governmental authority, costs in connection with export and import procedures and customs formalities and costs of carriage, insurance and
freight. 

  
 (4)

 “Party” or “Parties” shall mean COBALT or PFIZER, or both, depending
upon the context in which either word may appear. 
 “PPI” shall mean the United States Producer Price Index for
pharmaceutical preparation manufacturing, as published by the Bureau of Labor Statistics on its website (www.bls.govioni), or if not available from such website, then as published by the Bureau of Labor Statistics in its monthly periodical
“Producer Price Indexes.” 
 “Product” or “Products” whenever
used herein shall mean PFIZER’s NDA-approved atorvastatin calcium product, labeled and packaged for distribution into generic drug channels, as identified in Exhibit A. For avoidance of doubt, the Products shall not include any product
containing (i) any active pharmaceutical ingredient other than atorvastatin calcium, or (ii) any pharmaceutical product marketed under the marks Lipitoe) or Caduce or any similar marks. 
 “Reporting Period” shall mean a three-month period corresponding to a Calendar Quarter. 
 “Specifications” shall mean all Product, regulatory, manufacturing, quality control, and quality assurance procedures, processes, practices, standards, instructions and specifications comprising
PFIZER’s FFDCA approval applicable to the manufacture and packaging of Product as set forth in the NDA, and such other FDA and/or other regulatory requirements as may be applicable. 

“Specific Product” shall mean a specific dosage strength of a Product. 

“Supply Price” shall mean the prices at which PFIZER sells the Product to COBALT pursuant to Section 4.1. 

“Term” has the meaning set forth in Section 8.1 
 “Territory” shall mean the United States of America, its territories, commonwealths and possessions. 
 “Third Party” shall mean any person, entity or other organization (other than the Parties and their respective Affiliates). 

Any other capitalized terms used but not defined in this Article I shall have the meanings assigned to such terms in the body of this
Agreement. 

  
 (5)

	II.	SCOPE OF AGREEMENT 

  

	2.1	(a) The Parties shall submit this Agreement, and any ancillary agreements, and the Canada Supply Agreement to the Federal Trade Commission (“Commission”)
Bureau of Competition (“Bureau”) for review as promptly as practical after the Execution Date, but no later than April 25, 2008. Each of the Parties agrees to use its reasonable best efforts to fully cooperate with any Bureau
investigation that may ensue as a result of such submission. If any government investigation is instituted each Party shall use its reasonable best efforts to defend the Agreement in any such investigation and to resist and contest any proposals or
efforts to materially alter the terms thereof so as to permit the Parties to fulfill their obligations under and to obtain the full benefits contemplated by this Agreement. 

(b) Notwithstanding any other provisions of this Agreement, the Parties agree that either Party may terminate this Agreement and the
proposed Consent Judgment and Order of Court which shall be null and void if, within twenty-one (21) days after this Agreement and the proposed Consent Judgment and Order of Court are submitted to the Commission: 

(1) the Commission authorizes its staff to intervene, or otherwise participate, in the Litigation to oppose this
Agreement, or the proposed Consent Judgment and Order of Court, or 
 (2) the Commission votes to initiate its
own judicial or administrative litigation against any of the Parties related to this Agreement or the proposed Consent Judgment and Order of Court. 
 (c) If none of the events set forth in Section 2.1(b) above have occurred within the twenty-one (21) day period set forth in Section 2.1(b), the Parties shall submit the proposed Consent
Judgment and Order of Court to the United States District Court for the District of Delaware (the “Court”) and request that such Court enter the proposed Consent Judgment and Order of Court. If the Court enters the Consent Judgment and
Order of Court, this Agreement shall take effect as of the date of the Court’s entry of the Consent Judgment and Order of Court (such date, the “Effective Date”). If the Court refuses to enter the proposed Consent Judgment and Order
of Court, then this Agreement and the proposed Consent Judgment and Order of Court shall be null and void as of the Execution Date, subject to Section 2.1(d) of this Agreement. 

  
 (6)

 (d) If any of the events set forth in Section 2,1(b) of this Agreement occurs before
entry of the proposed Consent Judgment and Order of Court, or if the Court refuses to enter the proposed Consent Judgment and Order of Court, then either Party may terminate this Agreement as of the Execution Date, and the Agreement shall be null
and void. 
 (e) If at any time the Agreement is rendered null and void or if PFIZER cannot fulfill its obligations pursuant to
Section 2.2 hereto, then PFIZER and COBALT shall within ten (10) days of that event take whatever steps are necessary to vacate the Consent Judgment and Order of Court. If the Agreement is rendered null and void or if PFIZER cannot fulfill
its obligations pursuant to Section 2.2 hereto, the Consent Judgment and Order of Court shall riot constitute or be offered as evidence of an admission by COBALT that U.S. Patent No. 5,273,995 is valid, If the Agreement is rendered null
and void or if PFIZER cannot fulfill its obligations pursuant to Section 22 hereto, the Consent Judgment and Order of Court shall not constitute or be offered as evidence of an admission by COBALT that U.S. Patent No. 5,273,995 is
enforceable. If the Agreement is rendered null and void or if PFIZER cannot fulfill its obligations pursuant to Section 2.2 hereto, the Consent Judgment and Order of Court shall not constitute or be offered as evidence of an admission by COBALT
that U.S. Patent No. 5,273,995 is infringed by COBALT’s proposed atorvastatin sodium product in New Drug Application, No. 22-245. It is the intent of the parties that in the event that the Agreement is rendered null and void or if
PFIZER cannot fulfill its obligations pursuant to Section 2,2 hereto, that COBALT shall not be in any way prejudiced with respect to its defenses and counterclaims now pending in the Action. 

 

	2.2	 Subject to the terms and conditions of this Agreement and effective as of the Commencement Date, PFIZER hereby appoints COBALT as, and COBALT hereby
accepts its appointment as, PFIZER’s exclusive (even as to PFIZER) authorized distributor of the Products in the Territory during the Term. Such appointment grants to COBALT the exclusive right to market, sell, promote and distribute Products
in the Territory after the Commencement Date during the Term, and PFIZER shall not grant to any Third Party (including Greenstone Limited or any other Affiliate of PFIZER) the right to, market, sell, promote or distribute the Products in the
Territory during the Term. COBALT may not assign, transfer or delegate (whether by sublicense or otherwise) any of the foregoing appointment or rights to any Third Party, except as may be agreed in writing by PFIZER in its sole discretion (any such
Third Party approved in writing by PFIZER, an “Authorized Sublicensee”). For the avoidance of doubt, no Third Party to whom 

  
 (7)

	 	
COBALT sells Products in the ordinary course of the exercise of its rights to market, sell, promote and distribute the Products in the Territory shall be deemed to be an assignee, transferee,
delegate, and/or sublicense. The foregoing does not grant to COBALT any right to market, sell, promote or distribute the Products in a combined form with any other pharmaceutical product. For avoidance of doubt, the foregoing shall not be construed
to prohibit or limit in any manner PFIZER’s right to (a) market, sell, promote or distribute any pharmaceutical product other than the Product in the Territory, including without limitation PFIZER’s products, or any pharmaceutical
product that combines atorvastatin calcium with any other active pharmaceutical ingredient (including, without limitation, PFIZER’s Caduee product) or (b) grant to any Third Party the right to do any of the same. Pursuant to the terms and
conditions of this Agreement, commencing on the Commencement Date, COBALT shall purchase exclusively from PFIZER, and PFIZER shall exclusively supply to COBALT, such total quantities of Products as COBALT may require to market, sell, promote and/or
distribute the Products in the Territory. 

  

	2.3	COBALT shall not market, sell, promote or distribute the Products (a) prior to the Commencement Date, (b) outside the Territory, (c) to any purchaser or
distributes that COBALT knows intends to utilize, resell or redistribute the Products outside the Territory, or (d) for any use, within or outside of the Territory, that is not a use for which PFIZER has received approval from the FDA. In the
event that COBALT becomes aware of, or PFIZER notifies COBALT that, a Third Party is utilizing, reselling or redistributing any Products sold or distributed by or on behalf of COBALT hereunder in violation of this Section 2.3, COBALT shall
immediately cease all sale and distribution of the Products to such Third Party and COBALT shall use its Commercially Reasonable Efforts to cause such Third Party to cease such violation. Without limiting the foregoing, COBALT shall be responsible
for compliance with the terms and conditions of this Agreement by itself and all of its Affiliates and Authorized Sublicensees used to market, promote, distribute and sell the Products. COBALT shall use Commercially Reasonable Efforts to promote the
Products, exercising substantially the same diligence and adhering to substantially the same standards that it employs with respect to its other products. 

  

	2.4	COBALT will have the right in its sole discretion to establish the price at which the Products will be sold to third parties. 

 

	2.5	Notwithstanding anything to the contrary in this Agreement, PFIZER shall not be obligated to supply Products to COBALT and COBALT shall not be permitted to sell
Products during any time period in which there is in effect an injunction or similar court order prohibiting the manufacture, marketing, distribution, sale or use of the Products or PFIZER’s Lipitor product in the Territory.

  
 (8)

	2.6	COBALT acknowledges that PFIZER will need to adjust its manufacturing, supply and distribution activities in the event that COBALT, after receiving all necessary FDA
and other approvals of COBALT’s 505(6)(2) application for its atorvastatin sodium product, commences the sale of such product, Accordingly, COBALT shall notify PFIZER at least ninety (90) days in advance of COBALT’s commercial
introduction and sale of its atorvastatin sodium product in the Territory (such required notice, a “COBALT Launch Notice”). 

  

	2.7	Except for the rights expressly granted to COBALT pursuant to this Agreement, PFIZER does not grant to COBALT, whether by implication, estoppel or otherwise, any rights
or interests in or to the Products or any Intellectual Property therein or relating thereto, or any right to reference the NDA. Nothing in the Agreement shall be deemed to (a) constitute any agreement, acquiescence or admission on the part of
PFIZER as to the propriety of COBALT’s Section 505(b)(2) application for its atorvastatin sodium product or (b) prohibit PFIZER from challenging such application in any proceeding brought before the FDA or any court or other
governmental or regulatory body. 

  

	III.	FORECASTS AND SUPPLY 

  

	3.1	Subject to the terms and conditions of this Agreement, PFIZER shall use its Commercially Reasonable Efforts to maintain quantities of the Product that are sufficient
for COBALT to commence the introduction and sale of the Product in the Territory immediately after the occurrence of the Commencement Date. In furtherance of the foregoing, PFIZER shall maintain in the United States at least the equivalent of three
(3) months’ inventory of each strength of the Product in finished goods form for use in supplying COBALT’s initial requirements for the Product, it being understood that the Product in such inventory may be comprised of PFIZER’s
Lipitor product and as a result may not satisfy all of the requirements relating to tablet size, shape and embossing agreed to by the Parties pursuant to Section 3.2. In the event that the Commencement Date occurs prior to November 30,
2011, PFIZER will ship such inventory per COBALT’S instructions for delivery at COBALT’S facilities as specified in section 5.1 to arrive not later than five (5) days after the Commencement Date, 

  
 (9)

	3.2	Within ninety (90) days of the Effective Date, the Parties shall meet to discuss launch strategy for the Product after the Commencement Date as well as
requirements with respect to the Product to be sold by COBALT immediately after the occurrence of the Commencement Date, including without limitation the size, shape and embossing of the Product tablets, the design of and specifications for the
packaging and labeling of the Product, the initial quantity of Product to be delivered to COBALT to cover the period from the Commencement Date through the date on which PFIZER delivers the quantities of Product ordered by COBALT pursuant to the
first binding purchase order submitted by COBALT pursuant to Section 3.4, and the invoice terms for such initial delivery of Product. Such requirements shall be mutually agreed to in writing by the Parties and attached hereto as an integral
part of this Agreement. Upon the request of either Party, the Parties shall meet from time to time to discuss any desired changes to such requirements. 

  

	3.3	Within thirty (30) days following any Commencement Date, COBALT shall prepare and deliver to PFIZER a forecast of non-binding estimated quarterly purchases for
each of the Calendar Quarters remaining in the calendar year in which the Commencement Date occurs. Thereafter, on the first day of each Calendar Quarter, COBALT will provide PFIZER rolling quarterly forecasts, each forecast covering a one year
period. The forecast for the first quarter covered by the forecast may not increase or decrease by more than twenty-five percent (25%) from the most recent previous forecast for that quarter. 

 

	3,4	No later than ninety (90) days following any Commencement Date, COBALT and PFIZER shall seek in good faith to negotiate and agree upon the schedule and terms by
which COBALT will provide PFIZER with firm purchase orders for, and PFIZER’s delivery schedule for, each of the Products. All purchase orders will be in full-lot quantities, and submitted at least thirty (30) days in advance of expected
delivery during the initial ninety (90) day period following the Commencement Date and, thereafter, at least ninety (90) days in advance of expected delivery. Except as may be agreed by PFIZER, PFIZER shall not be required in any case to
fulfill any quantity of Product ordered pursuant to COBALT’s purchase order that exceeds the amount of Products included in the then applicable first Calendar Quarter of the current forecast. 

 

	3.5	PFIZER will manufacture, package, label, store, and ship the Products in accordance with COBALT’S directions, but in all cases subject to the Specifications set
forth in the NDA as such NDA may be amended from time to time. COBALT’s Quality Control personnel, upon reasonable prior notice to PFIZER, shall be permitted to observe the manufacture of Products being manufactured by PFIZER for COBALT. In the
event that PFIZER cannot reasonably manufacture Product in accordance with the Specifications, PFIZER shall promptly so advise COBALT. PFIZER shall promptly notify COBALT of any governmental action or other event or 

  
 (10)

 Confidential Portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

 

	 	
circumstance of which PFIZER becomes aware that PFIZER reasonably believes may materially affect its ability to manufacture or have manufactured the Product in the quantities required by COBALT
under this Agreement. 

  

	3.6	Each purchase by COBALT of Products shall be governed only by the terms of this Agreement and none of the terms or conditions in COBALT’s forms (whether contained
in a purchase order, invoice, acknowledgement or other) shall be applicable. 

  

	3.7	Returns by customers or others to COBALT of Products shall be the responsibility and obligation of COBALT alone, except as set forth in Section 6.2 and 7.2.

  

	3.8	PFIZER may have, on or after the Commencement Date, additional or different bottle sizes or blisters of the Product available for commercial sale. Upon COBALT’s
written request, PFIZER shall supply to COBALT pursuant to the terms and conditions of this Agreement such additional or different bottle sizes or blisters at the per tablet Supply Price set forth in Exhibit B-1. 

 

	IV.	PAYMENTS AND REPORTS 

  

	4.1	COBALT shall remit payment for shipments of Product delivered by PFIZER to COBALT in U.S. dollars within [**] days of PFIZER’s invoice. The invoice shall be issued
by PFIZER only after shipment of the Product and shall reflect the Supply Price as of the date of shipment by PFIZER for each dosage strength of the Product, The Supply Prices shall be as follows: 

(a) in the event that the Commencement Date is prior to November 30, 2011, the applicable Supply Price for each dosage strength of
the Product shall be those prices set forth on Exhibit B-1 attached hereto, which provides for the supply prices for the initial 180 days after the Commencement Date (the “Initial 180 Day Period”) as well as for the remainder of the
initial period up to the first anniversary of the Commencement Date (the “Remainder of Initial ‘Year Period”), subject to the adjustments contemplated by Section 4.2(b) and Section 4.2(c) below; and 

(b) in the event that the Commencement Date is November 30, 2011, the applicable Supply Price for each dosage strength of the Product
shall be those prices set forth in the Initial 180 Day Period in Exhibit B-1 attached hereto. However, when a Third Party makes the Generic Product available for purchase in commercial quantities (meaning at least 10% or more availability to major
wholesalers, retail pharmacy chains and managed care providers sufficient to meet a significant portion (at least 10%) of such Third Party’s initial stocking requirements), the 

  
 (11)

 Confidential Portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

 
 
applicable Supply Price for the first 180 days after such entry by the Third Party shall be the prices set forth in the Initial 180 Day Period in Exhibit B-1 attached hereto, subject to the
adjustments contemplated by Section 4.2(b) and Section 4.2(c) below. Immediately upon the 181ST day after such entry by the Third Party, the applicable Supply Price shall be the prices set forth in the Remainder of Initial Year Period in Exhibit 13-1, also subject to the adjustments contemplated by
Section 4.2(b) and Section 4.2(c) below. 
 Ninety (90) days prior to the end of each of the first anniversary and
each succeeding anniversary of the Commencement Date, COBALT and PFIZER agree to discuss in good faith the establishment of a new schedule of Supply Prices. If the Parties do not agree on a new schedule of Supply Prices, the Supply Prices set forth
on Exhibit B-1 under the heading “Remainder of Initial Year Period” (subject to the adjustments contemplated by Section 4.2(b) and Section 4.2(c) below), plus an increase equal to the increase in the PPI for each Calendar Quarter
thereafter in which shipment of Product occurs with such PPI calculated and compounded quarterly), shall continue to be effective. 
  

	4.2	(a) Within forty-five (45) days following the end of each Reporting Period, COBALT will determine the quantity of each dosage strength of the Product sold by
COBALT, its Authorized Sublicensees and/or their respective Affiliates during the Reporting Period, and the corresponding Net Sales and aggregate Supply Price associated with the units sold by COBALT, its sublicensees and/or their respective
Affiliates during the Reporting Period. Additionally, within forty-five (45) days following the end of each Reporting Period, COBALT will provide PFIZER with ending inventory quantities for each dosage strength of each Product as of the end of
each Reporting Period. 

 (b) In the event that [**] percent ([**]%) of such Net Sales is in excess of the
aggregate Supply Price, COBALT shall pay to PFIZER the amount of such excess. Such payment by COBALT shall be made within sixty (60) days after the Reporting Period. 
 (c) In the event that the aggregate Supply Price is in excess of [**] percent ([**]%) of such Net Sales, PFIZER shall pay to COBALT the amount of such excess, provided that PFIZER shall not be
required to pay any such amount to COBALT if such payment would result in the aggregate Supply Price to be less than the minimum Supply Price specified in Exhibit B-2. Such payment by PFIZER shall be made within sixty (60) days after the Reporting
Period. 

  
 (12)

 (d) The calculations set forth in clauses (b) and (c) above shall be made on a
Reporting Periodby-Reporting Period basis and consistent with clause (a) above. 
  

	4.3	COBALT shall keep such records as are accurate to determine the payments due PFIZER and the calculations required to be made pursuant to Section 4.2. Such records
shall be retained by COBALT and shall be made available for reasonable review or audit, at PFIZER’s request and expense, by a certified public accountant appointed by PFIZER and reasonably acceptable to COBALT for the purpose of verifying
COBALT’s calculation of the amounts due under Section 4.2 hereunder and of determining the correctness of such calculation and the payments due PFIZER. Such records shall be retained for at least five (5) years from the date of their
origin, or two (2) years after the date of termination of this Agreement, whichever occurs first, but need not be retained more than five (5) years from the date of their origin or more than two (2) years after the date of the
termination of this Agreement, whichever is appropriate, or as otherwise required by law. If PFIZER requests an audit, such records shall be retained for one (1) year from the date of such request but need not be retained more than one
(1) year after the completion of any audit thereof requested by PFIZER. 

  

	4.4	All payments required to be made to PFIZER under this Agreement shall be made in United States dollars and, with respect to any payments for amounts invoiced, in the
manner specified in such invoice, and in respect of any other payments required hereunder, by transfer on the due date to the following address: 

  

			
		 	Pfizer Inc.
		 	235 East 42nd Street
		 	New York, New York 10017-5755

 or to any other address that PFIZER may advise in writing. 

All payments required to be made to COBALT under this Agreement shall be made in United States dollars and, with respect to any payments
for amounts invoiced, in the manner specified in such invoice, and in respect of any other payments required hereunder, by transfer on the due date to the following address: 

 

			
		 	Cobalt Laboratories Inc.,
		 	 24840 South Tamiami Trail

Bonita Springs, Florida 34134

 Or such other address as COBALT shall designate in writing. 

 

	4.5	Any amount owing to a Party under this Agreement that is not paid when due shall bear interest at the U.S. Prime Rate as published by Citibank, NA that is applicable to
the date on which the payment was first due. 

  
 (13)

	V.	SHIPPING 

  

	5.1	All shipments of Products from PFIZER to COBALT will be shipped FOB Pfizer’s shipping dock in the United States, and delivered to such COBALT facility in the
United States as COBALT may specify in writing from time to time, and will be in accordance with the reasonable instructions for shipping and packing set forth in the relevant COBALT purchase order. Each order will be shipped to a single
destination. Title and risk of loss or damage to the Products shall pass to COBALT upon delivery to the designated carrier at PFIZER’s shipping dock in the United States. Any and all transportation costs after delivery for the Product shall be
paid by COBALT. 

  

	VI.	PRODUCTS TESTING/INSPECTION 

  

	6.1	PFIZER shall perform quality assurance testing with respect to the Products sold hereunder, including stability and return product complaint sample testing in
conformance to PFIZER’s policies. PFIZER shall provide the results thereof to COBALT in the form of a Certificate of Analysis (hereinafter “COA”). PFIZER shall also provide COBALT with Material Safety Data Sheets (hereinafter
“MSDS”) as required for the Products, and updates of same as necessary. COBALT will permit PFIZER’s personnel, upon reasonable notice, to visit at reasonable intervals, and for reasonable durations during regular business hours, any
COBALT facility used for the storage and distribution of the Products and will allow such personnel to perform a quality assurance audit and or review and make copies of any relevant records in connection therewith. The Parties will cooperate in
good faith to develop a procedure for handling the reporting of any cOMP information necessary for PFIZER to complete required Quality Product Complaint Investigations and required reporting, i.e. annual product reviews and Annual Reports pursuant
to meeting our regulatory reporting requirements. 

  

	6.2	 COBALT shall have a period of thirty (30) days from the later of (a) the date of COBALT’s receipt of the Products at the COBALT facility
designated in the purchase order, or (b) the date of COBALT’S receipt of the COA’s applicable to such Products, to inspect any shipment of Products to determine whether such shipment conforms to the Specifications. If COBALT
determines that the Products do not conform in all material respects to the Specifications, it shall 

  
 (14)

	 	
immediately notify PFIZER. COBALT’s failure to notify PFIZER within the stipulated period shall be deemed, for purposes of this Agreement, as COBALT’S acceptance of such shipment and
shall constitute a waiver of any right COBALT may have to reject such shipment subject, however, to COBALT’s right to reject Products for latent defects discovered by COBALT after such stipulated period has expired provided such notice is
provided by COBALT to PFIZER within twenty (20) days following the discovery of such latent defects. If PFIZER agrees that the Products do not conform to the Specifications, COBALT shall return the non-conforming Products to PFIZER, at a
location designated by PFIZER and at PFIZER’s expense. PFIZER shall use Commercially Reasonable Efforts to replace any non-conforming Products thereafter. 

 

	6.3	In the event PFIZER does not agree with COBALT’S determination that the Products fail to meet the Specifications, the Parties shall, in good faith, attempt to
resolve such dispute. In the event the Parties cannot resolve said dispute among themselves they shall submit the matter to an independent Third Party testing laboratory agreeable to both COBALT and PFIZER for a binding advisory opinion. The
expenses of obtaining the advisory opinion shall be borne by the Party against whom the dispute is decided by such laboratory. If the Parties are unable to agree on a Third Party testing laboratory, then either Party is free to pursue any legal,
equitable or administrative remedies to which it may be entitled. 

  

	VII.	REGULATORY AND MEDICAL INQUIRY 

  

	7.1	PFIZER shall remain responsible for maintaining and fulfilling all regulatory requirements in the Territory with respect to the Products that are imposed by Law upon
PFIZER as the manufacturer of the Products and the holder of the NDA in connection therewith. COBALT shall be responsible for obtaining, maintaining and fulfilling all regulatory requirements in the Territory with respect to the Products that are
imposed by Law upon COBALT in connection with COBALT’s marketing, distribution and sale of the Products. Each Party will, on a timely basis, provide the other Party with all information that such Party has that the other Party does not have
that is reasonably necessary and relevant to either Party’s obligations in fulfilling such requirements. COBALT and PFIZER shall cooperate in the reporting of adverse drug experience information and other post marketing reports as are required
to be filed with the FDA or its equivalent. COBALT shall submit to PFIZER all complaints, adverse drug experience reports and other medical inquiries associated with the Products within two (2) business days of COBALT’s receipt of such
reports. PFIZER will be responsible for fulfilling any regulatory requirements with respect to such events, including but not limited to the filing of all Form FD 2253’s, and will make any necessary contact with the FDA regarding the subject
matter of same. The Parties will cooperate in good faith to develop a procedure for handling adverse drug experience reports, 

  
 (15)

	7.2	In the event COBALT or PFIZER shall be required or requested by any governmental authority (or shall voluntarily decide) to recall any Products because such Products
may violate any Laws or for any other reason, the Parties shall cooperate fully with one another in connection with any recall. To the extent a recall is due to a latent defect notified to PFIZER pursuant to Section 6.2 or to PFIZER’s
negligence, willful misconduct or material breach of this Agreement, PFIZER shall reimburse COBALT for the Supply Price paid by COBALT for such recalled Products, all of the reasonable costs and expenses actually incurred by COBALT in connection
with the recall including, but not limited to, costs of retrieving Products already delivered to customers, costs and expenses COBALT is required to pay for notification, shipping and handling charges, and such other costs as may be reasonably
related to the recall. To the extent a recall is due to COBALT’s negligence, willful misconduct or material breach of this Agreement, COBALT shall remain responsible for the Supply Price for such recalled Products and shall reimburse PFIZER for
all the reasonable costs and expenses described above in the immediately preceding sentence actually incurred by PFIZER in connection with such recall, including without limitation administration of the recall and such other actual costs as may be
reasonably related to the recall. To the extent a recall results from a cause other than the negligence, willful misconduct or material breach of this Agreement of or by COBALT or PFIZER, the Parties shall share equally, all of the costs of the
recall (but excluding the Supply Price). Prior to any reimbursements pursuant to this Section, the Party claiming any reimbursement shall provide the other Party with reasonably acceptable documentation of all reimbursable costs and expenses.
Notwithstanding anything herein to the contrary, neither Party will be liable to the other under this Section 7.2 for consequential damages or lost profits of any kind. 

 

	7.3	 COBALT shall be responsible for filing and maintaining all documentation and other information as required by each and every state and locality
(hereinafter “State”) for the purpose of listing the Products on each such State’s forrnulary or other similar authority, and for obtaining such other approvals as may be necessary to market, promote, sell and distribute the Products
in the Territory. PFIZER shall provide COBALT, at COBALT’s expense, with such assistance as reasonably necessary to obtain such listings. COBALT will pay Medicaid and other applicable rebates required by Law or contract with respect to the
Products sold by it, If for any reason COBALT does not obtain the requisite regulatory approvals and formulary listings and as a result 

  
 (16)

	 	
is not able to distribute and sell the Products in the Territory, COBALT shall reimburse PFIZER for all expenditures made or commitments given by PFIZER in obtaining the production materials
required to be procured to manufacture the Products and the production and delivery of the Products pursuant to this Agreement. 

  

	7.4	in the event either Party receives notice of an inspection or other notification by a governmental entity, including the FDA, directly relating to the Products,
promotional materials or other matters within the scope of this Agreement, such Party shall notify the other Party as soon as practicable, and provide to such other Party, within ten (10) days, copies of all relevant documents as such other
Party may reasonably request. COBALT and PFIZER agree to cooperate with each other during any inspection, investigation or other inquiry by the FDA or any other governmental entity relating to the Products, including providing information and/or
documentation, as requested by the FDA or other governmental entity. 

  

	7.5	Notwithstanding anything to the contrary set forth elsewhere herein, COBALT shall have the right, without PFIZER’ s prior approval, to promote and publicize the
Products in its customary fashion, and may publicize such information about the Products as it usually and customarily provides for its own products utilizing its usual and customary channels of communication, and its standard forms, which may be
revised from time to time, provided that such promotion and publicizing of the Products conforms with all applicable Laws and is consistent with the Specifications and NDA. COBALT shall use its own branding in connection with its marketing,
promotion, sale and distribution of the Products, and may not use the PFIZER name or any PFIZER trademark, including without limitation Lipitor, or any confusingly similar variation thereof, in connection with such branding, the Products or
otherwise without PFIZER’s prior written consent. Without limiting the foregoing, tablets of the Product shall be embossed with COBALT’s own branding or, with respect to Product delivered to COBALT immediately after the Commencement Date,
with such branding as may otherwise be mutually agreed in writing by the Parties. 

  

	7.6	COBALT agrees not to repackage or otherwise alter the form of the finished packaged Products delivered to COBALT from PFIZER without the prior written permission of
PFIZER. 

  
 (17)

	VIII.	TERM AND TERMINATION 

  

	8.1	Subject in all cases to Section 2.1, the term of this Agreement shall begin on the Effective Date and shall end five (5) years after the initial Commencement
Date (“Term”). Upon mutual written agreement of the Parties, the Term shall be extended for one (1) or more consecutive one (1) year renewals of the Term. 

 

	8.2	(a) If either Party shall at any time fail to abide by or fail to perform in any material respect in accordance with any of the terms and conditions of this
Agreement, the other Party shall have the right to terminate this Agreement upon sixty (60) days’ notice to the defaulting Party specifying the default complained of, setting forth the underlying reasons for its belief that a default has
occurred and the remedy sought, provided that such notice of termination shall not be effective if the defaulting Party has cured such breach within such sixty (60) day period. 

(b) If either Party (i) institutes or has instituted against it any insolvency, receivership, bankruptcy or other proceedings for the
settlement of that Party’s debts, and such proceedings are not dismissed within sixty (60) days, (ii) makes a general assignment for the benefit of creditors, or (iii) dissolves, the other Party may terminate this Agreement
without notice. 
 (c) PFIZER may terminate this Agreement upon written notice effective immediately in the event that COBALT
challenges in any lawsuit, action or other legal proceeding the ownership, validity or enforceability of any of PFIZER’s Intellectual Property in or relating to the Products, including without limitation the ‘104, ‘156, ‘893,
‘995 and ‘971 patents and the other patent rights therein. 
 (d) PFIZER may terminate this Agreement upon ninety
(90) days’ notice if PFIZER and its Affiliates have ceased all marketing and sales activities relating to atorvastatin-based pharmaceutical products other than as a result of any transaction including the assignment or transfer or
sublicense of its rights relating to atorvastatin-based pharmaceutical products to any Third Party. 
 (e) Notwithstanding
anything else contained herein, if COBALT fails to pay when due any amount owing to PFIZER hereunder and fails to cure such default within thirty (30) days of notice thereof, then PFIZER shall have the right to terminate this Agreement
immediately without further notice. 
 (f) PFIZER shall have the right to terminate this Agreement on written notice effective
immediately in the event that (i) COBALT shall have delivered the COBALT Launch Notice, (ii) COBALT has failed to deliver the COBALT Launch Notice in breach of its obligation under Section 2,6, or (iii) COBALT has commenced the
commercial sale of any atorvastatin sodium product in the Territory. 

  
 (18)

	8.3	Expiration or termination of this Agreement for any reason shall be without prejudice to: 

 

	 	(a)	PFIZER’s right to receive all payments from COBALT due with respect to COBALT’s purchase of Product prior to such expiration or termination or either
Party’s right to receive all payments from the other Party that are payable in the future with respect to the reconciliation to be performed pursuant to Section 4.2, if any; 

 

	 	(b)	Subject to Section 8.4, COBALT’s right to sell the Products remaining in its inventory, subject to the terms and conditions of this Agreement;

  

	 	(c)	Any and all obligations under Article DC; and 

  

	 	(d)	Any liabilities or obligations accrued as of the date of expiration or termination, 

 

	8.4	Following the expiration of the ninety (90) day period immediately following the effective date of termination of this Agreement, notwithstanding
Section 8.3(b), COBALT shall no longer be permitted to sell the Products, and COBALT promptly shall destroy any Products remaining in its inventory at such time. Promptly thereafter, an officer of COBALT shall certify in writing to PFIZER that
COBALT has fully complied with the provisions of this Section 8.4. 

  

	IX.	INDEMNIFICATION AND INSURANCE 

  

	9.1	COBALT agrees to indemnify, defend and hold PFIZER harmless from and against any Losses resulting from or arising out of (a) COBALT’s storage, handling,
marketing, promotion, distribution, sale and/or delivery of the Products; (b) the execution by COBALT of this Agreement, the performance or breach by COBALT of its representations, warranties or obligations under this Agreement; or (c) the
gross negligence or willful misconduct of COBALT, its employees or its agents in connection with this Agreement (collectively “COBALT Activities”), except to the extent such Losses result from or arise out of PFIZER Activities (as defined
in Section 9.2). 

  

	9.2	PFIZER agrees to indemnify, defend and hold COBALT harmless from and against any Losses resulting from or arising out of (a) PFIZER’s design, manufacturing,
testing, packaging, storage, handling, and labeling of the Products; (b) the execution by PFIZER of this Agreement, the performance or breach by PFIZER of its representations, warranties or obligations under this Agreement; or (c) the
gross negligence or willful misconduct of PFIZER, its employees or its agents in connection with this Agreement (collectively “PFIZER Activities”), except to the extent such Losses result from or arise out of COBALT Activities (as defined
in Section 9.1). 

  
 (19)

	9.3	A Party seeking indemnification (“Indemnified Party”) under Section 9.1 or Section 9.2 shall notify, in writing, the other Party (“Indemnifying
Party”) within thirty (30) days of the assertion of any claim or discovery of any fact upon which the Indemnified Party intends to base a claim for indemnification. An Indemnified Party’s failure to so notify the Indemnifying Party
shall not, however, relieve such Indemnifying Party from any liability under this Agreement to the Indemnified Party with respect to such claim except to the extent that such Indemnifying Party is actually denied, during the period of delay in
notice, the opportunity to remedy or otherwise mitigate the event or activity(ics) giving rise to the claim for indemnification and thereby suffers or otherwise incurs additional liquidated or other readily quantifiable damages as a result of such
failure. The Indemnifying Party, while reserving the right to contest its obligations to indemnify hereunder, shall be responsible for the defense of any claim, demand, lawsuit or other proceeding in which the allegations, if proved, would trigger
the Indemnifying Party’s obligations under Section 9.1 or 9.2. The Indemnified Party shall have the right at its own expense to participate jointly with the Indemnifying Party in the defense of any such claim, demand, lawsuit or other
proceeding, but the Indemnifying Party shall have the right to settle, try Or otherwise dispose of or handle such claim, demand, lawsuit or other proceeding on such terms as the Indemnifying Party shall deem appropriate, subject to any reasonable
objection of the indemnified Party. Any settlement agreed to by the Indemnifying Party over the objection of the Indemnified Party may only provide a monetary relief and may not include any admission of liability or injunctive relief or other action
restricting the Indemnified Party. 

  

	9.4	Insurance. COBALT will provide PFIZER, no later than thirty (30) days prior to the Commencement Date, with evidence of insurance reflecting the
comprehensive general liability and products liability programs it has in effect. 

  

	X.	CONFIDENTIAL INFORMATION 

10.1 Confidential Information is any information relating to the business or business plans of a Party including, without limitation,
know-how, formulas, trade secrets, clinical or non-clinical data, processes, specifications, suppliers or customers. Except as provided below, during the Terra and for five (5) years thereafter, neither Party shall release to any Third Party
any Confidential Information of the other Party or any information with respect to the existence and 

  
 (20)

	 	
terms of this Agreement without the prior written consent of the other, not to be unreasonably withheld, and neither Party shall use the Confidential Information of the other Party for any
purpose not contemplated by this Agreement. Neither COBALT nor PFIZER shall issue any press release or public announcement with respect to the Agreement without the prior consent of the other as to the form and content of such release, except as
such release or announcement may be required by Law or by applicable stock exchange rules. 

  

	10.2	The obligations of confidentiality and non-use of each Party under this Article X shall not apply to information to the extent the receiving Party can demonstrate that
such information: (a) is or has become generally available to the public, without any breach by the receiving Party of the provisions of this Agreement or any other applicable agreement between the Parties; (b) was rightfully in the
possession of the receiving Party, without confidentiality restrictions, prior to such Party’s receipt pursuant to this Agreement; (c) was rightfully acquired by the receiving Party from a Third Party who was entitled to disclose such
information, without confidentiality or proprietary restrictions; or (d) was independently developed by the receiving Party without using or referring to the disclosing Party’s Confidential Information. 

 

	10.3	If either Party determines that a release of information concerning this Agreement is required by applicable Law, legal process (including without limitation any
subpoena or discovery ordered by any court of competent jurisdiction) or by stock exchange rules, it shall notify the other in writing at least ten (10) days (or such shorter period where legally required) before the time of the proposed
release; it being understood and agreed that each such Party that proposes to make any such release of information shall use its Commercially Reasonable Efforts to ensure that any such release shall not include more information regarding the
existence or terms of this Agreement than is required by Law, legal process or by stock exchange rule and shall seek the highest level of confidentiality then available for such information proposed to be released. Such notice shall include the
exact text of the proposed release and the time and manner of the release. At the other Party’s request, and before the release, the Party desiring to release further information shall consult with the other Party on the necessity for the
disclosure and the text of the proposed further disclosure. COBALT and PFIZER recognize that in addition to the other exceptions set forth herein, disclosure of this Agreement to 1RS and other tax authorities is likely to be required, and COBALT and
PFIZER each waives the requirements of this subsection with respect to disclosure to such entities. 

  
 (21)

	XI.	REPRESENTATIONS AND WARRANTIES 

  

	11,1	Representations, Warranties and Covenants by PFIZER. PFIZER hereby represents and warrants and covenants to COBALT as of the Effective Date as follows:

 (a) PFIZER is a corporation duly organized and validly existing under the laws of the State of Delaware;

 (b) PFIZER has the requisite corporate authority to execute and deliver this agreement and to perform its obligations
hereunder; 
 (c) Any Products delivered by PFIZER to COBALT shall, at the time of shipment, meet the Specifications and have
been manufactured, packaged, stored and shipped by PFIZER in compliance with the Specifications and in conformance in all material respects with CGMPs, Specifications, and any other applicable Laws, and shall not be adulterated, misbranded or
otherwise violative of the FFDCA or other applicable Laws in any material respect; 
 (d) The Products delivered by PFIZER to
COBALT shall have an expiration date that is not less than twenty-four (24) months from the date of PFIZER’s shipment thereof to COBALT; and 
 (e) PFIZER has and will maintain throughout the Term all permits, licenses, registrations and other forms of governmental authorization and approval as required by Law in order for PFIZER to execute and
deliver this Agreement and to perform its obligations hereunder in accordance with all applicable Laws. 
  

	11.2	Representation, Warranties and Covenants by COBALT. COBALT hereby represents and warrants and covenants to PFIZER as of the Effective Date as follows:

 (a) Cobalt Pharmaceuticals Inc. is a corporation duly organized and in good standing under the laws of Canada
and Cobalt Laboratories Inc. is a corporation duly organized and in good standing under the laws of Delaware; 
 (b) COBALT has
the requisite corporate authority to execute and deliver this Agreement and to perform its obligations hereunder; 
 (e) COBALT
has and will maintain throughout the Term all federal, state and local permits, 

  
 (22)

	 	
licenses, registrations and other forms of governmental authorization and approval as required by Law in order for COBALT to execute and deliver this Agreement and to perform its obligations
hereunder; and 

 (d) COBALT will perform its obligations hereunder in accordance with all applicable Laws, and
shall test, store, handle, market, promote, sell and distribute the Products in accordance with all applicable Laws and the Specifications. 
  

	11.3	 Disclaimer. Except as set forth in Section 11,1, PFIZER MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS, IMPLIED OR OTHERWISE, OF ANY KIND
WITH RESPECT TO THE PRODUCTS OR THE MANUFACTURE, SALE, DISTRIBUTION OR USE THEREOF; AND PFIZER HEREBY DISCLAIMS AND SHALL NOT BE RESPONSIBLE FOR ANY OR ALL OTHER REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OR REPRESENTATIONS OF
WORKMANSHIP, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. 

  

	11.4	Limitation of Liability. THE PARTIES AND THEIR AFFILIATES, EMPLOYEES, AGENTS, OFFICERS AND DIRECTORS SHALL NOT BE LIABLE IN ANY WAY WHATSOEVER FOR ANY INDIRECT,
SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES SUFFERED BY THE OTHER PARTY, OR ANY THIRD PARTY, INCLUDING WITHOUT LIMITATION LOST PROFITS OR BUSINESS REVENUE OR OTHER ECONOMIC LOSS OF ANY KIND WHATSOEVER, WHETHER OR NOT SUCH DAMAGES ARE FORESEEABLE OR
SUCH PARTY, ITS AFFILIATES, EMPLOYEES, AGENTS, OFFICERS OR DIRECTORS HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO EVENT SHALL THE TOTAL COLLECTIVE LIABILITY OF A PARTY AND/OR ITS AFFILIATES, EMPLOYEES, AGENTS, OFFICERS AND DIRECTORS
FOR A PARTICULAR CLAIM, REGARDLESS OF VALUE OR NATURE, EXCEED THE AMOUNTS PAID UNDER THIS AGREEMENT BY SUCH LIABLE PARTY TO THE OTHER PARTY. THE FOREGOING PROVISIONS OF THIS SECTION 11.4 SHALL NOT APPLY WITH RESPECT TO ANY DAMAGES OR LOSSES, ARISING
OUT OF A PARTY’S AND/OR ITS AFFILIATES, EMPLOYEES, AGENTS, OFFICERS OR DIRECTORS, REPRESENTATION OR WARRANTY THAT IS INTENTIONALLY FALSE OR INACCURATE OR ARISING OUT OF OR RESUL’IING FROM A WILLFUL MATERIAL BREACH BY THE PARTY AND/OR ITS
AFFILIATES, EMPLOYEES, AGENTS, OFFICERS 

  
 (23)

	 	
OR DIREUI ORS, OF ITS DUTIES OR OBLIGATIONS HEREUNDER OR AN ACT OR OMISSION CONSTITUTING GROSS NEGLIGENCE OF THE PARTY AND/OR OF ITS AFFILIATES, EMPLOYEES, AGENTS, OFFICERS OR DIRECTORS.

  

	XII.	NOTICES 

  

	12.1	Any notices or reports required or permitted under this Agreement shall be in writing and shall be deemed to have been given for all purposes if mailed by first class
certified or registered mail or transmitted electronically be facsimile with mailed confirmation copy to the following address of either Party: 

  

			
	 For COBALT:
	    	Cobalt Pharmaceuticals Inc.
		    	6500 Kitimat Road
		    	Mississauga, Ontario
		    	Canada L5N 2B8
		    	Attn: President
		
	 For PFIZER:
	    	Pfizer Inc.
		    	235 East 42nd Street
		    	 New York, New York 10017-5755

Attn: Office of the General Counsel

 or to such other addresses as shall have been subsequently furnished by written notice to the other Party. 

For purposes of communication between the Parties for purposes of cooperation or operational matters as contemplated herein, COBALT designates Rod
Johnson and PFIZER designates David Simmons, as its respective contact person for each Party with respect to the foregoing and who each may be contacted at the respective Party addresses as set forth above in this Section 12.1. Each Party may
change its designated contact person upon notice to the other Party consistent with the notice provisions of this Section 12.L 
  

	XII.	GOVERNING LAW AND PARTIES BOUND 

  

	13.1	Governing Law. The validity and interpretation of this Agreement and the legal relations of the Parties to it shall be governed exclusively by the internal laws,
and not the law of conflicts, of the State of New York. The Parties each hereby submit to the non-exclusive jurisdictions of federal and stale courts in the State of New York for the purposes of any suit, action or other proceeding relating to this
Agreement. Each Party irrevocably and unconditionally waives any objection to 

  
 (24)

	 	the laying of venue of any action, suit or proceeding arising out of this Agreement or the transactions contemplated hereby in the federal or state courts of the State
of New York, and hereby irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. 

 

	13.2	Parties Bound. This Agreement shall be binding upon and inure to the benefit of the Parties and their successors and assigns. This Agreement and the rights
granted herein may not be assigned or transferred (whether by contract, operation of law or otherwise) by COBALT without the prior written consent of PFIZER, provided that the acquisition of all or substantially all of the assets or business of
COBALT, by a Third Party shall not constitute a prohibited assignment or transfer under this Section 13.2. PFIZER may assign or transfer its rights and obligations hereunder to any Affiliate or to a successor or assignee of all or substantially
all of PFIZER’s relevant pharmaceutical business or assets, without COBALT’s prior consent. Notwithstanding anything to the contrary contained herein, PFIZER shall be free to delegate any and all of its obligations under this Agreement to
an Affiliate or Third Party, including without limitation to use any one or more contract manufacturers to produce and package the Product (including without limitation any active pharmaceutical ingredient and/or finished tablets).

  

	XIV.	FORCE MAJEURE 

  

	14.1	Subject to Section 2.1, which shall control where applicable, if either Party is prevented from complying, either totally or in part, with any of the terms or
provisions set forth herein (other than for any payment obligations hereunder), by reason of force majeure, including, by way of example and not of limitation, fire, flood, explosion, storm, strike, lockout or other labor dispute, riot, war,
rebellion, accidents, acts of God, acts of governmental agencies or instrumentalities (including, but not limited to, lack of a sufficient governmentally- mandated quota of the Products) or any other cause or externally induced casualty beyond its
reasonable control, whether similar to the foregoing continuencies or not, said Party shall provide written notice of same to the other Party. Said notice shall be provided within ten (10) working days of the occurrence of such event and shall
identify the requirements of this Agreement or such of its obligations as may be affected and to the extent so affected, said obligations shall be suspended during the period of such disability. The Party prevented from performing hereunder shall
use Commercially Reasonable Efforts to remove such disability, and shall continue performance whenever such causes are removed. The Party so affected shall give to the other Party a good 

  
 (25)

	 	
faith estimate of the continuing effect of the force majeure condition and the duration of the affected Party’s nonperformance. If the period of any previous actual nonperformance of PFIZER
because of PFIZER force majeure conditions plus the anticipated future period of PFIZER nonperformance because of such conditions will exceed an aggregate of one hundred eighty (180) days within any twenty-four (24) month period, COBALT
may terminate this Agreement by notice to PFIZER. If the period of any previous actual nonperformance of COBALT because of COBALT force majeure conditions plus the anticipated future period of COBALT nonperformance because of such conditions will
exceed an aggregate of one hundred eighty (180) days within any twenty-four (24) month period, PFIZER may terminate this Agreement by notice to COBALT. The provisions of Sections 8.3 and 8.4 and Article XXI shall apply in the event of any
such termination. When such circumstances as those contemplated herein arise, the Parties shall discuss in good faith, what, if any, modification of the terms set forth herein may be required in order to arrive at an equitable solution.

  

	XV.	NO ORAL MODIFICATIONS 

  

	15.1	No change, modification, amendment or waiver of any obligation, term or provision contained herein shall be valid or enforceable unless the same is reduced to writing
and signed by a duly authorized representative of each of the Parties to be bound hereby. 

  

	XVI.	INDEPENDENT CONTRACTORS 

  

	16.1	This Agreement shall not constitute or give rise to any employer-employee, agency, partnership or joint venture relationship among or between the Parties, and each
Party’s performance hereunder is that of a separate, independent entity. 

  

	XVII.	NO IMPLIED RIGHTS 

  

	17.1	Nothing in this Agreement shall be deemed or implied to be the grant by one Party to the other of any right, title or interest in the Products, Intellectual
Property or any other proprietary right of the other except as is expressly provided for herein. 

  

	XVIII.	SEVERABILITY 

  

	18.1	To the extent any provision or term set forth herein is or becomes unenforceable by operation of Law, such unenforceability shall not affect the remaining provisions of
this Agreement. The Parties agree to renegotiate in good faith any provision or term held to unenforceable and to be bound by the mutually agreed substitute provision. 

  
 (26)

	XIX.	MODIFICATION BY OPERATION OF LAW 

  

	19.1	If any of the terms or provisions of this Agreement are in or come into conflict with any applicable Law within the Territory then such term or provision shall be
deemed inoperative to the extent it may conflict therewith and shall be deemed to be modified to conform with such Law unless such modification would render the affected provision inconsistent with or contrary to the intent of the Parties. However,
in the event the terms and conditions of this Agreement are materially altered as a result of this subsection, the Parties shall in good faith attempt to renegotiate said terms and conditions to resolve any disputes related thereto.

  

	XX.	CAPTIONS 

  

	20.1	Article and section headings are provided for convenience only and are not to be used in construing the intent of the Parties. 

 

	XXI.	SURVIVORSHIP 

  

	21.1	The provisions of Sections 2.1, 8.3, 8.4, 11.3 and 11.4, and Articles IV, VII, LX, X, XII, XIII, XV, XVI, XVII, XVIII, X_LX, XX, XXI, XXII, XXIII, XXIV, XXV and XXVI
shall survive any expiration or termination of this Agreement. 

  

	NAM,	ENTIRE AGREEMENT 

  

	22.1	This Agreement, including the Exhibits attached hereto, contains the entire agreement between the Parties with respect to the subject matter hereof and supersedes all
prior drafts or understandings. 

  

	XXIII.	WAIVER 

  

	23.1	The waiver by either Party to this Agreement of a breach of any provision set forth herein or of any right contained herein shall not operate as or be construed as a
continuing waiver or a waiver of any subsequent breach or right granted herein. 

  

	LXIV.	SINGULAR AND PLURAL 

  

	24.1	The singular form of any noun or pronoun shall include the plural when the context in which such a word is used is such that it is apparent the singular is intended to
include the plural or vice versa, 

  
 (27)

	XXV.	COUNTERPARTS 

  

	25.1	This Agreement may be executed in two (2) counterparts each of which is to be considered an original and taken together as one and the same document.

  

	XXVI.	DOCUMENT PREPARATION 

  

	26.	The Parties acknowledge that this Agreement is a product of negotiations and that no inference should be drawn regarding the drafting or preparation of this document.

  
 (28)

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed in duplicate by
their duly authorized representatives in the places provided below, 
  

									
	COBALT PHARMACEUTICALS INC.	 		 	PFIZER INC.
					
	By	 	 /s/ T. Tabatznik
	 		 	 By

	 	 /s/ Marguerite Sells

	Title	 	Under Power of Attorney	 		 	 Title
	 	Under Power of Attorney
	Date	 	18 April 2008	 		 	 Date
	 	18 April 2008
				
	COBALT LABORATORIES INC.	 		 		 	
					
	By	 	 /s/ R. P. Jackson
	 		 		 	
	Title	 	C.E.O	 		 		 	
	Date	 	April 18, 2008	 		 		 	

  
 (29)

 ANNEX I 
 CONSENT JUDGMENT AND ORDER OF COURT 
 IN THE UNITED
STATES DISTRICT COURT 
 FOR THE DISTRICT OF DELAWARE 

 

					
	 		
	 PFIZER INC,
	  		  	
	 PFIZER IRELAND PHARMACEUTICALS,
	  		  	
	 WARNER-LAMBERT COMPANY,
	  		  	
	 WARNER-LAMBERT COMPANY, LLC
	  		  	
	 and WARNER-LAMBERT EXPORT LTD.,
	  		  	
			
	 Plaintiffs/Counterclaim-Defendants
	  		  	
			
	v.	  		  	C.A. No.07-790-J.IF
			
	 COBALT PHARMACEUTICALS, INC.,
	  		  	
			
	 Defendant/Counterclaim-Plainti ff.
	  		  	

 CONSENT JUDGMENT AND ORDER OF COURT 

WHEREAS, plaintiffs/counterclaim defendants Pfizer Inc, Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, Warner-Lambert Company, LLC and
Warner-Lambert Export Ltd. (“Pfizer”), and defendant-counterclaim plaintiff Cobalt Pharmaceuticals Inc. (“Cobalt”) stipulate that: 
 1. Cobalt admits that U.S. Patent No. 5,273,995 (“the ‘995 patent”) would be infringed by the commercial manufacture, use, offer to sell or sale within the United States or importation
or causing, directly or indirectly, the importation into the United States the proposed product that is the subject of Cobalt’s New Drug Application (“NDA”) 22-245, comprising atorvastatin sodium, 

  
 (30)

 Cobalt admits that U.S. Patent No. 5,273,995 is valid and enforceable and waives its
defenses and counterclaims in the above-captioned action. 
 3. Any Protective Order entered by the Court in
this action shall remain in full force and effect notwithstanding this Judgment and Order. 
 4. The parties waive any right of appeal from this Judgment and
Order. 
 5. Each party shall bear its own costs, expenses and attorneys’ fees in connection with this action. 

NOW THEREFORE, IT IS ORDERED AND ADJUDGED, on consent of the parties, that judgment shall be entered in favor of plaintiffs Pfizer Inc,
Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, Warner-Lambert Company, LLC and Warner-Lambert Export Ltd. and against defendant Cobalt Pharmaceuticals Inc that Cobalt has infringed United States Patent No. 5,273,995; and it is further

 ORDERED AND ADJUDGED that judgment shall be entered in favor of Pfizer and against Cobalt, dismissing all counterclaims
alleging and seeking declarations of non-infringement, invalidity or unenforceability of the ‘995 patent; and it is further 
 ORDERED that, pursuant to the provisions of 35 U.S.C. §271(e)(4)(A), the effective date of any approval of Cobalt’s
 NDA 22-245, seeking FDA approval of atorvastatin sodium tablets, 10, 20,
40 and 80 mg dosage strengths, shall be a date which is not earlier than the date of expiration of the ‘995 patent (December 28, 2010); and it is further, 
 ORDERED that, pursuant to the provisions of 35 U.S.C. §271(e)(4)(B), Cobalt, its officers, agents, servants, employees and attorneys, and those persons in active concert or participation with Cobalt
are enjoined until the date of expiration of the ‘995 patent (December 28, 2010) 

  
 (31)

 
from engaging in the commercial manufacture, use, offer to sell, or sale within the United States, or importation into the United States, of any product comprising the chemical compound atorvastatin sodium covered
by, or the sale or use of which is covered by, the ‘995 patent. 
  

									
	 Dated: April             , 2008
	 		 	Dated: April             , 2008
			
	CONNOLLY BOVE LODGE & HUTZ	 		 	YOUNG CONAWAY STARGATT & TAYLOR, LLP
					
	By:	 	  
	 		 	By:	 	  

		 	 Rudolf E. Hutz (#484)
 Jeffrey
B. Bove (#998)
 Mary W. Bourke (#2356)

The Nemours Building
 1007 North Orange Street
Wilmington, DE 19899
 (302)-658-9141

rhutz@eblh.com
 Attorneys for Plaintiffs
Pfizer Inc,
 Pfizer Ireland Pharmaceuticals,
 Warner-Lambert Company, Warner-Lambert Company, LLC and Warner-Lambert Export Ltd.
	 		 		 	 John Shaw (;13362)
 Jeffrey T.
Castellano (#4837)
 The Brandywine Builiding
 1000 West
Street, 17m Floor

Wilmington DE 19899
 (302)-571-6600

jshaw@ycst.com
 Attorneys for Defendant Cobalt
Pharmaceuticals, Inc.

 IT IS SO ORDERED, this
                     day of                     ,
2008. 

	
	  

	 The Honorable Joseph J. Farnan, Ir.
 United States District Judge

  
 (32)

 EXIABIT A  

PRODUCTS 
  

					
	Atorvastatin calcium	 	10mg	    	Packs of 90 tablets
	Atorvastatin calcium	 	20mg	    	Packs of 90 tablets
	Atorvastatin calcium	 	40mg	    	Packs of 90 tablets
	Atorvastatin calcium	 	80mg	    	Packs of 90 tablets

  
 (33)

 Confidential Portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

 
 EXHIBIT B-1 

 

					
	Initial 180 Day Period
			
	10 mg	 	in packs of 90 tablets.	  	$[**] per tablet
	20 mg	 	in packs of 90 tablets	  	$[**] per tablet
	40 mg	 	in packs of 90 tablets	  	$[**] per tablet
	80 mg	 	in packs of 90 tablets	  	$[**] per tablet

  

					
	Remainder of Initial Year Period
			
	10 mg	 	in packs of 90 tablets.	  	$[**] per tablet
	20 mg	 	in packs of 90 tablets	  	$[**] per tablet
	40 mg	 	in packs of 90 tablets	  	$[**] per tablet
	80 mg	 	in packs of 90 tablets	  	$[**] per tablet

  
 (34)

 Confidential Portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

 
 EXHIBIT B-2 

 

					
	Minimum Supply Price
			
	10 mg	  	in packs of 90 tablets	  	$[**] per tab
	20 mg	  	in packs of 90 tablets	  	$[**] per tab
	40 mg	  	in packs of 90 tablets	  	$[**] per tab
	80 mg	  	in packs of 90 tablets	  	$[**] per tab

  
 (35)Supply Agreement

 EXHIBIT 10.26 
 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a 

request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

SUPPLY AGREEMENT 
 SUPPLY AGREEMENT, dated as of November 1, 2010 (the “Agreement”), by and between Ortho-McNeil-Janssen Pharmaceuticals, Inc., a Pennsylvania corporation (“Seller”), and
Watson Laboratories, Inc., a Nevada corporation (“Purchaser”). 
 WHEREAS, Seller would like to make or have
made by its Affiliate and exclusively sell the Products (as defined below) to Purchaser, and Purchaser would like to exclusively purchase the Products from Seller pursuant to the terms of this Agreement; 

NOW, THEREFORE, in consideration of the mutual promises, covenants and agreements hereinafter set forth, the parties hereto agree
as follows: 
 SECTION 1 
 DEFINITIONS 
 As used throughout this Agreement and any exhibits, schedules
or attachments hereto, each of the following terms shall have the respective meaning set forth below: 
 1.1
“Additional Amount” shall have the meaning set forth in Section 2.3.3. 
 1.2
“Affiliate” of a party shall mean any entity that, directly or indirectly, controls, is controlled by, or is under common control with such entity (except as provided in Section 1.42). 

1.3 “Agreement” shall have the meaning set forth in the preamble. 

1.4 “ANDA” shall mean an Abbreviated New Drug Application filed with the FDA. 

1.5 “Appeal Arbitrator” shall have the meaning set forth in Section 17.2.7. 

1.6 “Bankruptcy Code” shall have the meaning set forth in Section 7.4. 

1.7 “Bankruptcy Laws” shall have the meaning set forth in Section 7.4. 

1.8 “Calendar Quarter” shall mean a calendar quarter based on Seller’s universal calendar for that
year and shall be updated by Seller for each Calendar Year of the term of this Agreement consistent with Seller’s universal calendar used for Seller’s internal business purposes; provided, however, that the first Calendar Quarter for the
first Calendar Year shall extend from the date of this Agreement to the end of the then current Calendar Quarter and the last Calendar Quarter shall extend from the first day of such Calendar Quarter until the effective date of the termination or
expiration of the Agreement. Upon Purchaser’s written request, Seller shall provide Purchaser with a copy of Seller’s universal calendar from the Start Date through December 31, 2014. 

  

 Execution Copy 

 
 1.9 “Calendar Year” shall
mean a calendar year during the term of this Agreement based on Seller’s universal calendar for that year. The last Calendar Year of the term of this Agreement shall begin on the first day of Seller’s universal calendar for the year during
which termination or expiration of the Agreement will occur, and the last day of such Calendar Year shall be the effective date of such termination or expiration. 

1.10 “Change in Control” shall mean: (i) the liquidation or dissolution of Purchaser’s publicly
listed parent corporation, Watson Pharmaceuticals, Inc., a Nevada Corporation (“WPI”) (or of Purchaser) or the sale or other transfer by WPI (or by Purchaser) (excluding transfers to Affiliates) of all or substantially all of its assets;
(ii) the occurrence of a tender offer, stock purchase, other stock acquisition, merger, consolidation, recapitalization, reverse split, sale or transfer of assets or other transaction, as a result of which any person, entity or group other than
an Affiliate of WPI (a) becomes the beneficial owner, directly or indirectly, of securities of WPI representing more than 50% of the ordinary shares of WPI (or of Purchaser) or representing more than 50% of the combined voting power with
respect to the election of directors (or members of any other governing body) of WPI’s (or of Purchaser’s) then outstanding securities, (b) obtains the ability, through an event or series of events, to appoint a majority of the Board
of Directors (or other governing body) of WPI (or of Purchaser), or (c) obtains the ability to direct the operations or management of WPI (or of Purchaser) or any successor to WPI’s (or Purchaser’s) business. 

1.11 “COGS” shall have the meaning set forth in Section 3.2. 

1.12 Intentionally Omitted. 

1.13 “CPR” shall have the meaning set forth in Section 17.2.1. 

1.14 “DEA” shall mean the United States Drug Enforcement Administration, and any successor or replacement
agency. 
 1.15 “Equivalent Product” shall mean any pharmaceutical product which is manufactured
by a party other than Seller or its Affiliate pursuant to an ANDA which was approved by the FDA, which ANDA was approved as bioequivalent to the NDA Product. 
 1.16 “FDA” shall mean the U.S. Food and Drug Administration, and any successor or replacement agency. 

1.17 “FTC” shall mean the U.S. Federal Trade Commission Bureau of Competition. 

  
 2 

 Execution Copy 

 
 1.18 “Force Majeure Event”
shall have the meaning given in Section 11.1. 
 1.19 “GAAP” shall have the meaning set
forth in Section 1.25. 
 1.20 “Indemnity Claim” shall have the meaning set forth in
Section 16.3. 
 1.21 “Initial Order” shall have the meaning set forth in
Section 2.3.1. 
 1.22 “Loss Leader” shall mean discounting the Product to a customer as an
inducement to purchase additional or other products or services from Purchaser or its Affiliates or increase the level of business such customer would have conducted with the Purchaser or its Affiliates. 

1.23 “Material Change” shall have the meaning set forth in Section 5.2.1. 

1.24 “Minimum Amount” shall have the meaning given on Exhibit B. 

1.25 “Net Sales” shall mean, with respect to any Product, the gross amounts invoiced from the sale of
such Product by Purchaser, its Affiliates and assignees to independent Third Parties in an arms-length transaction, in each case after subtracting the following to the extent specifically and solely allocated to such Product and actually taken,
paid, accrued, allowed, included or allocated based on good faith estimates in the gross sales prices with respect to such sales (and consistently applied as set forth below): (i) all normal and customary discounts of any type or nature (such
as retroactive price reductions, cash discounts, volume discounts, chargebacks, allowances, rebates, returns and credits, excluding commissions for commercialization); (ii) compulsory payments and cash rebates related to the sales of such
Product paid to a government authority (or agent thereof) pursuant to governmental regulations by reason of any national or local health insurance program or similar program (such as Medicaid and Supplemental State Program rebates, Medicare Part D
“Donut Hole” Coverage Gap rebates and “Industry Fees” for Brand Drugs as required by the Patient Protection and Affordable Care Act as amended by the Health Care Education Affordability Reconciliation Act), to the extent allowed
and taken; and (iii) one percent (1%) of the gross Product revenues on a monthly basis to account for freight, shipping, insurance costs, excise taxes, use taxes, sales taxes and custom duties, and/or government charges imposed on the
sales of such Product. Net Sales shall be determined on an accrual basis in accordance with generally accepted accounting principles (“GAAP”) in the Territory (except for those items identified in clause (ii) and (iii) above that
are classified as operating expenses for GAAP purposes), applied on a basis consistent with Purchaser’s annual audited financial statements, with monthly Net Sales calculations in any year subject to adjustment pending completion of
Purchaser’s annual audit for that year. All such discounts, allowances, credits, rebates, and other deductions shall be fairly and equitably allocated to the Product and other 

  
 3 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

products of Purchaser and its Affiliates such that such Product does not bear a disproportionate portion of such deductions. For the avoidance of doubt, inclusion of the Products in
Purchaser’s portfolio rebate program or substantially similar customer rebate programs shall be permitted, provided that such program does not discount the Product at a rate or percentage that is greater than the rate or percentage of discount
applied to other products in the same program. 
 1.26 “NDA” shall mean New Drug Application
No. 021121, filed with the FDA, as amended or supplemented. 
 1.27 “NDA Product” shall
mean the products approved and marketed in the United States under NDA No. 021121, as amended or supplemented. 
 1.28 “Net Selling Price” shall have the meaning given in Section 3.1. 
 1.29 “NSP Report” shall have the meaning set forth in Section 3.1. 
 1.30 “Overdue Interest Amount” shall mean the Prime Rate of interest quoted as such in The Wall Street Journal on the first business day of the month during which an amount becomes
overdue under this Agreement, plus [**]%, calculated on an annual basis. 
 1.31
“Pharmacovigilence Agreement” has the meaning set forth in Section 10.1. 
 1.32
“Product” or “Products”, as applicable, shall mean each of the products listed on Exhibit A to this Agreement, and any other products the parties agree to include herein. 

1.33 “Purchase Price” has the meaning set forth in Section 3.1. 

1.34 “Purchaser Trademarks” shall have the meaning set forth in Section 5.4. 

1.35 “Quality Agreement” shall have the meaning set forth in Section 5.3. 

1.36 “Remaining Amount” shall have the meaning given in Section 3.5. 

1.37 “Specifications” shall mean the specifications for the design, composition, manufacture, packaging,
and/or quality control of the Products, as the same may hereafter be modified by mutual agreement of the parties in writing. 
 1.38 “Start Date” shall mean the earlier of (i) May 1, 2011, or (ii) the date on which a Third Party commercially launches a product in the Territory that is approved by
FDA under an ANDA for which the NDA Product is the reference-listed drug. 

  
 4 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

1.39 “Territory” shall mean the United States of America, including its territories and possessions
(including, but not limited to, the Commonwealth of Puerto Rico). 
 1.40 “Third Party” or
“Third Parties” shall mean any person or entity other than Seller, Purchaser, or their respective Affiliates. 
 1.41 “Total Cap” shall have the meaning set forth in Section 15.3(B). 
 1.42 “Wholesaler Affiliate” means a subsidiary or affiliate of Purchaser whose primary business is wholesale distribution of pharmaceutical products. A Wholesaler Affiliate shall not be
deemed to be an Affiliate of Purchaser. 
 SECTION 2 

PURCHASE OF PRODUCT 
 2.1 Purchase Obligations. 
 2.1.1 During the term of this Agreement,
Seller shall exclusively supply Purchaser with those quantities of Products as are ordered by Purchaser pursuant to this Agreement, and (subject to the provisions of Section 4.5) Purchaser shall exclusively purchase from Seller 100% of
Purchaser’s requirements for the Products; provided, however, Seller shall not be obligated to supply Purchaser with any Products in the event Purchaser has an inventory level of such Products in excess of [**] ([**]) weeks of the current
market demand as described in Section 4.2. 
 2.1.2 During the term of this Agreement (and subject to the provisions of
Section 4.5), Purchaser shall exclusively purchase from Seller the Products solely for distribution, marketing and sale in the Territory, and shall not purchase, market, distribute or sell any Products or any Equivalent Product in the Territory
which are not provided by Seller under this Agreement. As set forth in the last sentence of the definition of “Net Sales”, Purchaser may include Products in Purchaser’s portfolio rebate program or substantially similar customer rebate
programs; provided, however, Purchaser shall not use Products as a Loss Leader in such program or in any other arrangement. 

2.1.3 Purchaser acknowledges that Seller manufactures identical or similar products for sale by it or its Affiliates in the Territory and
to Third Parties outside of the Territory, and Seller shall not be restricted from such activities by virtue of this Agreement. Notwithstanding the foregoing, Seller agrees that it shall not market or sell any generic version of a Product through
its own sales organization or distribution channels (or those of any of its Affiliates) or through any Third Party in the Territory during the term of this Agreement. 

  
 5 

 Execution Copy 

 
 2.1.4 Nothing in this Agreement shall prohibit Purchaser from
continuing or undertaking its own development of any Equivalent Product, seeking regulatory approval of any such Equivalent Product, or undertaking manufacturing development and qualification, and limited manufacture (including third party
manufacturing) of stability batches and validation batches of Equivalent Products, in each case solely for purposes of seeking regulatory approval for such Equivalent Product; provided, however, that subject to the provisions of
Section 4.5 and during the term of this Agreement with respect to the applicable Product, the parties acknowledge that Purchaser shall not be permitted to sell in the Territory any Equivalent Product which it so manufactures during the term of
this Agreement. Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement shall be interpreted to preclude Purchaser from selling any Equivalent Products outside of the Territory or manufacturing in or outside of the
Territory such Equivalent Products solely for purposes of sales outside of the Territory so long as (i) such Equivalent Products do not use any confidential or proprietary information of Seller and (ii) such Equivalent Products are not
manufactured using the same or substantially similar trade dress or trade names as used for the Products in the Territory, unless required by law in the jurisdiction outside of the Territory in which Purchaser sells such Equivalent Products.

 2.2 Territory. 
 2.2.1 Purchaser shall only sell the Products in the Territory and shall not, directly or indirectly, offer such Products to any Third Party which Purchaser knows is going to market, distribute or sell
such Products, directly or indirectly, outside the Territory. 
 2.2.2 Purchaser shall immediately cease sale or distribution of
any Product to any Third Party who Purchaser knows is marketing, selling or distributing any of the Products, directly or indirectly, outside of the Territory. Purchaser shall also reasonably cooperate with Seller in investigating and tracing any
sales of the Products outside of the Territory. Any failure by Purchaser to cease shipments of Products to such a Third Party shall be deemed a material breach of this Agreement. 

2.3 Commencement of Supply. 
 2.3.1 Seller shall be obligated to commence supply of each Product to Purchaser as set forth on an initial order (“Initial Order”) from Purchaser. The quantities in such purchase order shall be
in the amounts set forth on Exhibit C to this Agreement. 
 2.3.2 Seller shall deliver to Purchaser the quantities of Products
subject to the Initial Order no later than April 15, 2011; provided that, in the event the Start Date is prior to April 15, 2011, Seller shall deliver to Purchaser the quantities of Products subject to the Initial Order on or prior to the
Start Date or as soon thereafter as Seller is able to do so taking into account its product availability and production capacity at such time. In the event the Start Date occurs prior to April 15, 2011, Seller shall be permitted to supply
rolling shipments of Products to Purchaser in order to fulfill Purchaser’s Initial Order in the manner set forth in this paragraph 2.3.2. 

  
 6 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

2.3.3 It is the intent of the parties that each Product supplied to Purchaser under this Agreement shall be delivered to retail pharmacies
on or after the Start Date. Consequently, if Product supplied to Purchaser under this Agreement is delivered to retail pharmacies earlier than the Start Date, then Purchaser shall pay to Seller, as liquidated damages (the “Additional
Amount”), an amount equal to (A) (i) the number of units of Product shipped or distributed by Purchaser to any retail pharmacies prior to the Start Date times (ii) Seller’s branded published direct price (i.e., list
price) for Seller’s branded version of such Product, less (B) the amount paid or payable by Purchaser to Seller for such Products under Section 3 below. The Additional Amount shall be Seller’s sole remedy (whether arising in
contract, tort or otherwise) for the premature sale of Products by Purchaser. 
 SECTION 3 

PRICING 

3.1 Transfer Prices. The purchase price (“Purchase Price”) for each Product purchased from Seller shall be a
percentage of Purchaser’s Net Selling Price for such Product, as calculated on a monthly basis in the percentages set forth on Exhibit B. The Net Selling Price (“Net Selling Price”) for a Product shall be calculated by dividing the
Net Sales for such Product (based upon the Products sold by Purchaser to customers during any particular calendar month), by the number of units of such Product so sold by Purchaser. The Purchaser shall within ten business (10) days after the
end of each calendar month, provide to Seller actual, definitive Net Selling Price information for such month (“NSP Report”). The parties will reasonably cooperate with each other and share such information as is reasonably necessary to
reconcile any differences between the last day of the month in a Calendar Quarter with the last day of the corresponding Gregorian calendar month. Such definitive Net Selling Price information shall contain reasonable details as to the calculation
of the Net Selling Price. For the purpose of calculating Net Selling Price, Net Sales of Products sold by Purchaser or its Affiliates to a Wholesaler Affiliate shall be deemed to have been made at the higher of (i) the actual transfer price
from Purchaser or its Affiliates to the Wholesaler Affiliate, or (ii) the average Net Sales price of such Product based on sales to Third Parties other than Wholesaler Affiliates during the month in which the sale was made. 

3.2 Minimum Amount. The parties acknowledge that the Minimum Amounts set forth on Exhibit B are equal to the cost of the
Products (“COGS”), as calculated by Seller, plus [**] percent ([**]%) of COGS. Starting in December 2011, Seller and Purchaser agree that the Minimum Amounts set forth on Exhibit B shall be updated on an annual basis based on COGS, as
calculated by Seller, provided to Purchaser by Seller. Seller agrees that any annual increase of COGS of each Product will not exceed [**] percent ([**]%) of COGS of the immediately preceding annual COGS of such Product, as applicable. Starting in
December 2011, Seller shall provide COGS for each Product thirty (30) days prior to the end of the Calendar Year. Purchaser shall have the right to review and audit 

  
 7 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

Seller’s calculation of COGS under the same audit guidelines which are applicable to Seller contained in Section 3.7. The Minimum Amounts for each Product shall be effective
January 1 of the year following the date Seller provides Purchaser with updated COGS. In the event the Net Selling Price is below the Minimum Amount for the Products, as applicable, for a period of [**] ([**]) consecutive months, each party
shall have the right to terminate this Agreement prior to the expiration of its term by giving [**] ([**]) months prior written notice of its intent to terminate; provided, however, prior to either party exercising such termination right, the
parties shall attempt in good faith to discuss the Minimum Amount and negotiate a resolution for a period of thirty (30) days. In the event either party issues a notice of termination pursuant to this Section 3.2, Purchaser shall use
commercially reasonable efforts to manufacture commercial quantities of Equivalent Product. If Purchaser is able to manufacture such commercial quantities of Equivalent Product prior to the end of the [**] month notice period, the Agreement
termination date shall be accelerated to the date Purchaser is ready to commercially launch its Equivalent Product; provided, however, that Purchaser shall provide Seller with at least thirty (30) days prior written notice of such date that
Purchaser is ready to commercially launch its Equivalent Product and such date shall be at least [**]([**]) months after the termination notice was given unless both parties agree otherwise. 

3.3 Samples. No samples, promotional products or similar free goods shall be provided by Seller under this Agreement,
unless otherwise agreed to by the parties. 
 3.4 Shipping Terms. The prices charged by Seller to Purchaser shall
be F.O.B., Seller’s facility in the Territory at which finished goods are packaged for shipment to Purchaser. 
 3.5
Payment Terms. The Purchase Price for each order of Product shall be paid in two (2) installments. The first installment shall be equal to the aggregate of the Minimum Amount times the number of units of such Product shipped for
the order, and shall be paid within thirty (30) days from the date of invoice for the order. Such invoice shall be sent at the time of shipment of such Product to Purchaser. The second installment (the “Remaining Amount”) shall be
equal to the greater of (i) the aggregate Purchase Price for such Product determined in accordance with Section 3.1, or (ii) from the Start Date until June 30, 2012, [**] percent ([**]%) of the branded wholesale acquisition cost
(WAC) for each calendar month, and from July 1, 2012 until the end of the term of the Agreement, [**] percent ([**]%) of the branded wholesale acquisition cost (WAC), less the aggregate Minimum Amount for such number of units of Product
sold during such month in each of (i) and (ii) above. The second installment shall be paid to Seller within thirty (30) days after the end of each calendar month. To the extent the Purchase Price is less than the Minimum Amount for
any particular month, Seller shall not be liable to Purchaser for such shortfall; provided, however, that Purchaser shall be entitled to accrue such shortfall and use such shortfall in subsequent periods during which the Purchase Price
exceeds the Minimum Amount. In the event there remains any accrued shortfall at the termination or expiration of this Agreement, such shortfall shall be extinguished at such time and Seller shall not be liable to Purchaser for any amounts related to
such shortfall. Any payments not made within the specified period of time for 

  
 8 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

payment shall incur an interest charge at the rate of the Overdue Interest Amount on such overdue amounts, excluding any amounts that are subject to a bona fide dispute between the parties. In
addition, Seller may withhold shipment of Product to Purchaser if Purchaser has failed to make any payment required under this Agreement (except for any amounts that are subject to a bona fide dispute) for a period of sixty (60) days or longer
after the due date for such payment. All payments shall be made through electronic transfer of funds or other wire transfers. 

3.6 Returns. During the term of the Agreement, total cumulative deductions for Product returns shall not exceed an amount
equal to [**] percent ([**]%) of Net Sales (disregarding, for the purposes of such calculation, any accrual for Product returns); provided that Product returns related to any Product recall(s) that are not the fault of Purchaser shall be excluded
from the foregoing limit. Notwithstanding the preceding sentence, Purchaser shall maintain an accrual for Product returns in a manner consistent with Purchaser’s generic prescription drug business generally, which accrual shall be factored into
the calculation of Product Net Sales as provided in Section 1.25. In the event there remains an accrual for Product returns at the termination or expiration of this Agreement, Seller shall neither be liable to nor obligated to reimburse
Purchaser for any such accrued amounts. Notwithstanding anything to the contrary and for the avoidance of doubt, any deductions for Product returns pursuant to this Section 3.6 shall only be applied to Remaining Amounts. 

3.7 Audit Rights. Purchaser shall keep accurate books and records for purposes of documenting the amount of the Net Sales
and Net Selling Price, and for purposes of determining if any sales of the Products are being made outside of the Territory. Said books of account shall be kept at Purchaser’s principal place of business. Upon at least five (5) business
days notice, Seller shall have the right to have a mutually agreeable neutral, independent public accounting firm obtain access to Purchaser’s financial records during reasonable business hours for the purpose of verifying, at Seller’s
expense, the amount of Net Sales, the calculation of the Purchase Price, and the calculation of credits, and the verification that all Product sales are being made solely for distribution within the Territory; provided, however, that
this right may not be exercised more than once in any year. Seller shall solicit or receive only information relating to the accuracy of such calculations or to verify the destination of such sales, and shall only have access to information for the
most recent two (2) Calendar Years. Purchaser shall be entitled to require such accountants to sign a confidentiality agreement in form and substance reasonable satisfactory to Purchaser. Any underpayment of the Purchase Price due to a
miscalculation by Purchaser of such amount shall be paid within thirty (30) days after the delivery of a final, detailed written accountants report to Purchaser. In the event any such audit reveals a shortfall in amounts paid to Seller of five
percent (5%) or more for any Calendar Year, then the reasonable costs of the accountant employed in order to perform such audit shall be reimbursed by Purchaser. In the event any such audit report reveals an overpayment by Purchaser, Seller
shall promptly provide such report to Purchaser and such overpayment shall be refunded by Seller to Purchaser within thirty (30) days after the receipt of the accountants’ report by Seller. Any underpayment or overpayment amount which is
paid pursuant to this Agreement will include interest on such amount from the original due date at the Overdue Interest Amount. 

  
 9 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

SECTION 4 

FORECASTS, ORDERS 
 4.1 Forecasts and Orders. Within five (5) days after the beginning of each calendar month during the term of this Agreement, Purchaser shall provide Seller with a written rolling
non-binding forecast (except as provided below) of Purchaser’s expected requirements for each Product during the following twelve (12) months. The first three months of each such forecast shall be binding for each of the Products. The
third month of each such forecast, which shall be binding, shall not vary from the corresponding month (fourth month) of the preceding forecast by an amount greater to or less than [**] percent ([**]%) for any increases, and [**] percent
([**]%) for any decreases. In the event of a significant change in market conditions, significant new competitive factors and/or new key customer demands, the parties agree to negotiate in good faith on appropriate changes to such forecasts.

 4.2 Orders. Purchaser shall submit binding written or electronic purchase orders for each Product (or by any
other means agreed to by the parties) to Seller, which shall be placed at least ninety (90) days prior to the desired date of delivery, and which binding orders shall comply with the binding forecasts set out in Section 4.1.
Notwithstanding anything to the contrary, Purchaser agrees to use commercially reasonable efforts not to maintain an inventory level of the Products in excess of [**] ([**]) weeks of the current market demand of such Products. From the Start Date
until September 30, 2011, such market demand shall be calculated based on eighty percent (80%) of the average monthly market demand for Seller’s NDA Product between January 1, 2011 and March 31, 2011. From October 1,
2011 until the end of the term of the Agreement, such market demand shall be calculated based on Purchaser’s actual average monthly market demand for Products during the preceding three (3) month period. For purposes of determining
Seller’s obligation to supply Purchaser with Products pursuant to this Agreement, each purchase order submitted by Purchaser shall be accompanied by a certification of Purchaser confirming that its inventory level of the Products at the
requested time of delivery is not expected to be in excess of [**] ([**]) weeks of such market demand. 
 4.3
Conflicts. To the extent of any conflict or inconsistency between this Agreement and any purchase order, purchase order release, invoice, confirmation, acceptance or any similar document, the terms of this Agreement shall govern.

 4.4 Capacity Allocation. In the event that Seller’s inability (including without limitation any inability
as a result of a Force Majeure Event) to meet firm orders is due to a shortage of production capacity or raw materials at Seller’s or its supplier’s facility or a failure to receive Products from its supplier, Seller shall promptly notify
Purchaser in writing of such shortage of production capacity, raw materials and failure of receipt, and, if possible, the date such shortage of production capacity or raw materials is expected

  
 10 

 Execution Copy 

 
 
to end or the date Seller expects to receive Products from its supplier. In the event of such shortage, Seller shall allocate its available production capacity or available raw material available
for the production of the NDA Product to be sold in the Territory to the production of Products in accordance with Exhibit D. 

4.5 Alternative Sources of Equivalent Products. In the event that Seller fails (for any or no reason including without
limitation any Force Majeure Event) to deliver all or any portion of an order of Product to Purchaser (other than the Initial Order) in accordance with the terms of this Agreement for a period of thirty (30) days or longer, Seller shall
promptly notify Purchaser of such fact. Purchaser shall have the option, but not the obligation, to purchase substitute Equivalent Product in the same quantities as Seller is unable to deliver to Purchaser from such Third Parties or other sources as
Purchaser shall determine. Purchaser shall be permitted to obtain such Equivalent Products from alternative sources solely for that period of time as Seller is unable to deliver Product to Purchaser under this Agreement. In the event Purchaser
elects to obtain such alternative products, Purchaser shall still be obligated to pay to Seller the Purchase Price amounts as calculated under Exhibit B; provided, however, that there shall be subtracted from such amounts
Purchaser’s actual direct cost of such alternative Equivalent Products. 
 SECTION 5 

SPECIFICATIONS 
 5.1 Specifications. 
 5.1.1 Seller shall provide Purchaser with the
Specifications for each of the Products no later than December 31, 2010. The Specifications for each Product shall not be changed except as permitted under this Agreement. 

5.1.2 The parties agree to cooperate in good faith to adopt new packaging for each Product. Purchaser shall provide its packaging
specifications for the Products to Seller no later than December 31, 2010. 
 5.2 Changes. 

5.2.1 From time to time during the term of this Agreement, either party may submit to the other written proposals for the adoption,
implementation or development of any change, improvement or modification to the Product. If such change is proposed by Seller, such change may be implemented by Seller after consultation with Purchaser (but without requiring Purchaser’s
consent) so long as such change does not negatively impact the safety or efficacy of the Products, increase Purchaser’s liability with respect to the Products, adversely impact the commercial value to Purchaser of the Products, or result in a
change to the tradename or basic packaging for the Product (any such change hereinafter referred 

  
 11 

 Execution Copy 

 
 
to as a “Material Change”). If such change is a Material Change, Seller shall not be permitted to make such change without the prior consent of Purchaser, such consent not to be
unreasonably withheld or delayed, and subject to the provisions of Sections 5.2.2 and 5.2.3 below. The Specifications shall be modified to reflect any such changes. In the event of any change, Seller shall establish an appropriate qualification
protocol, and Purchaser and Seller shall determine an appropriate inventory level for the pre-change Product in order to cover on-going requirements during the qualification process. The foregoing shall not preclude Seller from implementing process
changes or other manufacturing related changes so long as such changes do not (i) require any filing or notifications to the FDA or DEA and (ii) materially alter the Specifications. 

5.2.2 In the event that Seller is required to change the Product Specifications pursuant to applicable law, rule, or regulation or in
response to the order of a governmental authority or regulatory body, Seller shall promptly advise Purchaser in writing of any such change, as well as any scheduling adjustments which may result from such change. Seller shall bear a percentage of
all costs related to any such change required by the regulatory or governmental authority, such percentage calculated by multiplying such costs by the percentages set forth in Exhibit B for the corresponding period requiring such change, and
Purchaser shall bear the remaining percentage of such costs; provided, however, that if such change relates to Seller’s manufacturing facility generally or to equipment which is not specifically dedicated to the Products, then
Seller shall be responsible for such costs (subject to a reasonable allocation for that portion which is attributable to the Products). Upon request, Seller shall provide reasonable documentation of its costs related to such change and permit
Purchaser to review and audit such costs under the same audit guidelines which are applicable to Seller contained in Section 3.7. 
 5.2.3 In addition to the changes under Section 5.2.2, Purchaser shall also have the right to request that a change be made to the Specifications at its expense (including the expense of any materials
rendered obsolete as a result of such change) and upon prior written notice to Seller. Seller shall not be required to make any such change if (i) it results in the need for any capital investment by Seller, (ii) it results in any cost
increases (including manpower allocations or resources) to Seller, (iii) it requires any changes to the regulatory filings or status for the Product (other than items reportable in the NDA annual report required to be filed with FDA each year)
or (iv) it is commercially impracticable for Seller to implement (in its reasonable judgment). For any such change, Purchaser shall provide camera ready artwork (in digital format whenever reasonably available to Purchaser) consistent
with the Specifications if necessary to facilitate any changes to the Specifications. 

  
 12 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

5.3 Quality Agreement. The parties have agreed to enter into a Quality Agreement (e.g., to address change control issues)
(the “Quality Agreement”), which Quality Agreement will be negotiated in good faith and entered into as promptly as feasible after the date of this Agreement, in no event later than April 1, 2011. To the extent that any
inconsistencies exist between the Quality Agreement and this Agreement, the stipulations and provisions in this Agreement shall prevail. 
 5.4 Trademarks. All trademarks, tradenames and packaging graphics (collectively, the “Purchaser Trademarks”), if any, used by Purchaser in connection with the Products shall
be chosen by Purchaser in its sole discretion; provided, however, that Purchaser (i) shall choose such trademarks only after conducting diligent trademark clearance; and (ii) shall not be permitted to use any such Purchaser
Trademarks to the extent Seller, in its reasonable judgment, determines that such Purchaser Trademarks (i) will be confusingly similar to those which Seller uses in connection with any of its own similar products, or (ii) will be
confusingly similar to any other pharmaceutical product which is currently on the market. Purchaser shall be responsible for any and all costs associated with clearance, filing, and maintenance of the Purchaser Trademarks and all liabilities which
may arise from Purchaser’s use of the Purchaser Trademarks (including, but not limited to, any allegations of intellectual property infringement related thereto and any liabilities related to prescription errors related to such trademark
usage). Unless required by applicable law or regulation, Purchaser shall not use any trademark, tradename, company name, copyright or other intellectual property of Seller in connection with the distribution, marketing, promotion or sale of the
Product. For the avoidance of doubt, statements of equivalence such as, for example, “bioequivalent to
Concerta®” shall not be deemed to be a violation of the preceding sentence. 

5.5 Certificate of Analysis, Certificate of Compliance. Each shipment of Products to Purchaser shall be accompanied by a
certificate of analysis prepared by an authorized representative of Seller confirming that the Products in the shipment have been tested in accordance with the NDA and meet the Specifications and a certificate of compliance prepared by an authorized
representative of Seller confirming that the Products have been manufactured in accordance with this Agreement and the NDA. Any deviations and investigations related to such Products shall be documented by Seller in accordance with the NDA and the
Quality Agreement. 
 5.6 Expiry Dating. All Products shipped to Purchaser, at the time of shipment by Seller,
shall have expiry dating which is no more than [**] ([**]) months into the specified expiry schedule for such Product; provided, however, that (i) in no event shall any Product be shipped with less than [**] ([**]) months
remaining until its expiry date. Seller shall use reasonable efforts to ship Product to Purchaser with at least [**] ([**]) months remaining until its expiry date. 

  
 13 

 Execution Copy 

 
 5.7 Stability Testing. Seller shall maintain a
stability testing program for the Products and provide Purchaser with an annual product review thereon. In the event that any results from such program could indicate that Product would not meet its expiry date, Seller shall promptly notify
Purchaser. At least one (1) batch per year of each Product shall be included in the stability program. 
 5.8 Annual
Report. Purchaser shall supply distribution information and other required information to Seller for the purposes of inclusion into the NDA annual report to the FDA. 
 SECTION 6 
 TERM 

6.1 Term. The term of this Agreement shall commence on the date hereof and remain in effect for each Product hereunder
until December 31, 2014, unless sooner terminated as expressly provided under the terms of this Agreement. 
 SECTION 7

 TERMINATION 
 7.1 Intentionally Omitted. 
 7.2 Intentionally Omitted.
 

  
 14 

 Execution Copy 

 
 7.3 Breach. This Agreement may be terminated,
prior to the expiration of its term, by either party by giving written notice of its intent to terminate and stating the grounds therefor if the other party shall materially breach or materially fail in the observance or performance of any
representation, warranty, guarantee, covenant or obligation under this Agreement. The party receiving the default notice shall have sixty (60) days from the date of receipt thereof to cure the breach or failure, except in the case of a
financial breach (excluding those which are being disputed in good faith), in which case such cure period shall be fifteen (15) days. If a non-financial breach is not curable within such sixty (60) day period (other than a failure to
supply Product in accordance with the requirements of this Agreement), then the non-performing party shall have an additional ninety (90) days within which to cure such breach so long as the non-performing party is diligently working towards a
remedy for such breach. In the event such breach or failure is cured in accordance with the provisions of this Section 7.3, the default notice shall be of no effect. In the event such breach or failure is not cured in accordance with the
provisions of this Section 7.3, then this Agreement shall terminate without the requirement of the non-defaulting party providing any additional notice to the defaulting party. Notwithstanding the foregoing and for the avoidance of doubt, any
failure other than a willful failure of Seller to supply Product to Purchaser in accordance with the requirements of this Agreement , including a failure attributable to the shortage of raw materials as a result of the limitations imposed by the
DEA, shall not be deemed to be a breach under this Agreement so long as Seller is using its reasonable efforts to provide such supply of Product to Purchaser and, to the extent available, is supplying Products to Purchaser in the manner set forth in
Section 4.4. 
 7.4 Insolvency, Etc. This Agreement may be terminated, prior to the expiration of its term,
upon written notice by either party: (i) in the event that the other party hereto shall (1) apply for or consent to the appointment of, or the taking of possession by, a receiver, custodian, trustee or liquidator of itself or of all or a
substantial part of its property, (2) make a general assignment for the benefit of its creditors, (3) commence a voluntary case under the United States Bankruptcy Code, as now or hereafter in effect (the “Bankruptcy Code”),
(4) file a petition seeking to take advantage of any law (the “Bankruptcy Laws”) relating to bankruptcy, insolvency, reorganization, winding-up, or composition or readjustment of debts, (5) fail to controvert in a timely and
appropriate manner, or acquiesce in writing to, any petition filed against it in any involuntary case under the Bankruptcy Code, or (6) take any corporate action for the purpose of effecting any of the foregoing; or (ii) if a proceeding or
case shall be commenced against the other party hereto in any court of competent jurisdiction, seeking (1) its liquidation, reorganization, dissolution or winding-up, or the composition or readjustment of its debts, (2) the appointment of
a trustee, receiver, custodian, liquidator or the like of the party or of all or any substantial part of its assets, or (3) similar relief under any Bankruptcy Laws, or an order, judgment or decree approving any of the foregoing shall be
entered and continue unstayed for a period of 60 days; or an order for relief against the other party hereto shall be entered in an involuntary case under the Bankruptcy Code. 

  
 15 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

7.5 Change of Control. Seller may terminate this Agreement upon [**] ([**]) months prior written notice to Purchaser in the
event of a Change in Control in WPI or Purchaser. 
 7.6 Effect of Expiration or Termination. Termination of this
Agreement for any reason shall not release either party hereto from any liability which at such time has already accrued or which thereafter accrues from a breach or default prior to such expiration or termination, nor affect in any way the survival
of any other right, duty or obligation of either party hereto which is expressly stated elsewhere in this Agreement to survive such termination. In the case of a termination under Section 7.3 above, the non-defaulting party may pursue any
remedy available in law or in equity with respect to such breach, subject to the terms of Sections 15, 16 and 17. Any Products in Purchaser’s possession as of the date of expiration or termination of this Agreement shall be sold by Purchaser
and shall be subject to the terms of this Agreement. 
 SECTION 8 

DELIVERY; INVENTORY 
 8.1 Delivery. All charges for in-process storage, packaging and bar coding are included in the transfer price unless otherwise agreed to by the parties. Seller shall not be responsible for
warehousing finished goods for Purchaser and Seller shall ship all finished goods to Purchaser upon completion. Purchaser is responsible for any delivery charges FOB Seller’s packaging site in the Territory. All shipments must be accompanied by
a packing slip that describes the articles, states the purchase order number and shows the shipment’s destination. Deliveries of Product shall be made in accordance with the delivery schedule set forth in the purchase orders provided in
compliance with Section 4.2. 
 8.2 Shipment. The risk of loss with respect to Product shall be with
Purchaser once the Product leaves Seller’s packaging facility. Seller will pack all Product ordered hereunder in a manner suitable for shipment and sufficient to enable the Product to withstand the effects of shipping, including handling during
loading and unloading. Purchaser shall notify Seller within 24 hours of discovery of any lost or stolen goods to facilitate Seller’s notification of the FDA and the DEA. 
 SECTION 9 
 DEFECTIVE PRODUCT/INSPECTIONS/TESTING 

9.1 Disposition of Defective Product. Seller warrants that any Product sold to Purchaser hereunder shall comply in all
respects with the Specifications therefor. Seller shall replace at its own cost and expense, including reimbursement of freight and disposition costs incurred by Purchaser, Product that fails to comply with the Specifications. Purchaser shall,
within thirty (30) days after receipt of any shipment of Product, notify Seller of the existence and nature of any non-compliance or defect. If such notice is not provided within the thirty (30) day period, then all such Product shall

  
 16 

 Execution Copy 

 
 
be deemed to be in compliance with this Agreement. If Purchaser notifies Seller within such thirty (30) day period of any defective Products, then Seller shall have a reasonable opportunity,
not to exceed thirty (30) days from receipt of notification, to inspect such defective Products and provide Purchaser with detailed written instructions to return or dispose of such defective Products. If Seller fails to instruct Purchaser as
to the disposition of such defective Products, Purchaser may dispose of such defective Products as it sees fit. 
 9.2
Independent Testing. If, after Seller’s inspections of such Product, the parties disagree as to the Product’s conformance to the Specifications or whether the Product has such a defect, either party may deliver the Product to
an independent third-party laboratory, mutually and reasonably acceptable to both parties, for analytical testing to confirm the Product’s conformance to the Specifications or the presence or absence of defects. All costs associated with such
third-party testing shall be at Purchaser’s expense unless the tested Product is deemed by such third-party to not be in compliance with the Specifications, in which case all such costs, including reimbursement of freight and disposition costs,
shall be promptly paid by Seller. 
 9.3 Hidden or Latent Defects. As soon as either party becomes aware of a
hidden or latent defect in any Product lot, it shall immediately notify the other party of such event (including reasonable details and the lot involved). If a Product accepted by Purchaser becomes non-conforming by virtue of the later discovery of
a hidden or latent defect, Purchaser may place the lot on quality assurance hold pending Seller’s investigation and a final resolution of the claimed hidden or latent defect pursuant to Section 9.1 and 9.2 above. In the event that the
Product is found to contain a hidden or latent defect, the Product shall be deemed rejected pursuant to Section 9.1 and 9.2 as of the date of the notice, and the rights and obligations of the parties with respect to the rejected Product shall
thereafter be governed by Section 9.1 and 9.2. 
 9.4 Short-Shipment. Purchaser shall notify Seller within
thirty (30) days of receipt of any short-shipment claims with respect to the Product. 
 SECTION 10 

REGULATORY MATTERS 
 10.1 Reporting; Etc. Purchaser shall have the responsibility in the Territory for complying with all regulatory filings, reporting requirements and other matters which relate solely to
Purchaser’s acting as a distributor of the Product in the Territory. In the event Purchaser determines that it is required to file this Agreement with the United States Securities and Exchange Commission, Purchaser shall provide Seller with
reasonable prior notice of such requirement and shall request confidential treatment of the financial terms and other competitively sensitive or trade secret terms of this Agreement. All other regulatory reporting matters (including adverse event
and product complaint reporting) shall be Seller’s responsibility. Purchaser represents and warrants that Purchaser has in place systems and resources for tracking and reporting any adverse events with respect to the Product, such systems and
resources to be 

  
 17 

 Execution Copy 

 
 
consistent with good commercial standards in the pharmaceutical industry. Purchaser shall notify Seller of receipt of any report(s) of adverse events or product complaints pursuant to a
Pharmacovigilance Agreement. To the extent that any inconsistencies exist between the Pharmacovigilance Agreement and this Agreement, the stipulations and provisions in this Agreement shall prevail. Seller shall have the right to audit
Purchaser’s systems with respect to handling adverse event reporting in connection with the Products, any such audit to be done during normal business hours on reasonable notice, and in a fashion to avoid unnecessary disruption to normal
business operations. Any complaint or adverse event received by one party that relates to product manufacture or packaging must be reported to the other party within 3 business days. The Pharmacovigilence Agreement shall set forth additional details
with respect to the handling of adverse event reporting. 
 In order to ensure compliance with safety reporting requirements in the respective
Territories the parties shall agree on a process and procedure for sharing adverse event information which shall be documented in a Pharmacovigilance Agreement (the “Pharmacovigilence Agreement”). Within thirty (30) days from the
effective date of this Agreement each party shall assign a safety representative to begin discussions to ensure a Pharmacovigilence Agreement is executed no later than April 1, 2011. Pending execution of such agreement, the parties shall, as
required, within thirty (30) days implement an interim procedure for exchange of any and all information concerning adverse events related to use of the Product regardless of source to ensure each party’s compliance with legal requirements
in its respective territories. 
 10.2 FDA Communications. Purchaser and Seller agree to notify the other party
promptly in the event they receive any communication or notice from the FDA or the DEA with respect to the Products, and each party shall promptly provide a copy of such communications to the other. The parties shall cooperate in good faith in
responding to any such FDA or DEA inquiry or in making any report to the FDA or DEA with respect to the Products, but in all cases Seller shall have final authority for regulatory decisions concerning the Products and responsibility for all
communications with the FDA and the DEA. Notwithstanding the foregoing, to the extent any such communication or decision relates solely to the Products (and not Seller’s branded version of the Products), then Seller shall not make such
communication or decision without the prior consent of Purchaser, such consent not to be unreasonably withheld or delayed. 

10.3 Audits. Purchaser shall have the right, at Purchaser’ sole expense, to conduct an audit during Seller’s
normal business hours, upon written notice to Seller in accordance with the terms of the Quality Agreement (with such notice identifying any specific audit requests and necessary contact person), of Seller’s facilities which are involved in the
manufacture, processing, packaging, testing or storage of a Product. Purchaser shall have the right to conduct such audit no more than one (1) time per Calendar Year; provided, however, that in the event Purchaser has identified
any substantive, material quality issue involved with the manufacturing of the Product, then Purchaser shall be entitled to such reasonable number of additional follow-up audits as 

  
 18 

 Execution Copy 

 
 
may be needed to confirm the steps taken to rectify such issue. In no event shall an audit of a particular facility exceed two (2) days in duration or involve more than three
(3) representatives of Purchaser unless mutually agreed in writing by the parties. Purchaser warrants that all inspections and audits hereunder shall be carried out in a manner that does not unreasonably interfere with Seller’s normal and
ordinary conduct of business and that insures the continued confidentiality of Seller’s other business and technical information. Any such representatives shall be reasonably qualified in terms of auditing skill to conduct audits, shall execute
a written agreement to maintain in confidence all information obtained during the course of any such audit except for disclosure to Purchaser, and shall comply with Seller’s normal company policies and with security and safety regulations.

 10.4 Audit Feedback. Within thirty (30) days of completing any audit hereunder, Purchaser shall submit to
Seller a written report outlining its findings and/or observations from any such audit. If deficiencies are discovered during an audit that could, in Purchaser’s opinion, prevent Seller from satisfying the requirements of cGMP obligations
hereunder, and Seller in good faith disputes the observations or conclusions of Purchaser, then the Parties shall promptly enter into good faith discussions to resolve their differences. If the Parties fail to resolve their differences within thirty
(30) days after receipt of the audit report, then Seller’s opinion shall prevail; provided, however, that Purchaser shall not be prohibited from taking any action applicable to Purchaser that it is required to take under
applicable law. If Seller does not dispute the observations made during any audit it shall use its commercially reasonable efforts to correct those deficiencies at its own cost, and shall notify Purchaser in writing when those deficiencies are
corrected. 
 10.5 Recalls. Seller and Purchaser each shall notify the other promptly if any batch of Product
purchased by Purchaser pursuant to this Agreement is the subject of a recall or market withdrawal, and the Parties shall cooperate in the handling and disposition of such recall or market withdrawal; provided, however, in the event of
a disagreement as to any matters related to such recall or market withdrawal, other than the determination of who shall bear the costs as set forth in the immediately following sentence, Seller shall have the final authority with respect to any
Product recall or market withdrawal. Notwithstanding the foregoing, Purchaser shall not be restricted from taking any action required by law or regulation which Purchaser is advised by its legal counsel. Purchaser shall bear the cost of all recall
or market withdrawals of Product purchased by Purchaser pursuant to this Agreement unless such recall or market withdrawal shall have been the result of (i) Seller’s failure to manufacture the Product in accordance with the requirements of
this Agreement, or (ii) Seller’s breach of any of its obligations or warranties set forth in Section 15 hereof, in which case Seller shall bear the cost of such recall or market withdrawal, subject to the limitations set out in
Section 15.2. Purchaser shall maintain records of all sales of Product and customers sufficient to adequately administer a recall or market withdrawal for the longer of three (3) years after termination or expiration of this Agreement or
the period required by applicable law. Purchaser shall, in all events and regardless of who bears the cost, be responsible for administrating the physical aspects of any recalls or market withdrawals with respect to the Products. 

  
 19 

 Execution Copy 

 
 10.6 Batch Records. Batch records, including
information relating to the manufacturing, packaging, and quality control testing and analysis for each lot of finished Product produced hereunder, will be prepared as and when Seller performs any such tasks for such batch. Batch records and all
other records relating to production hereunder shall be retained by Seller for such period of time as is required under applicable rules and regulations of the FDA. Purchaser acknowledges that many of the batch records may be prepared in a foreign
language other than English and Seller shall not be obligated to translate into English such batch records. Upon Purchaser’s written request therefore, Seller shall furnish to Purchaser for any Calendar Quarter during the term of this
Agreement, a complete copy of an executed batch record for each SKU of Product produced during such quarter; provided, however, that Seller shall not be required to furnish any such information on more than one occasion during each Calendar Quarter.
Additionally, Seller shall, upon Purchaser’s written request in connection with any audit, make available for review by Purchaser during the course of such audit, updates to the validation package for each Product. All of Seller’s
obligations under this Section 10.6 shall be subject to the limitation that Seller shall be conducting such activities in accordance with its normal and customary procedures, and the parties acknowledge and agree that Seller shall not be
subject to any unique or special requirements in connection with the Products supplied hereunder to Purchaser. If Purchaser requests additional validation work, such work shall be performed at Purchaser’s cost. 

10.7 Complaints. Purchaser shall maintain complaint files for the Product in accordance with cGMP. Product quality
complaint reports received by Purchaser will be summarized and sent to Seller by e-mail to Central Complaint Vigilence Americas at the e-mail address JusaQA@janus.jnj.com. Product quality complaint reports received by Seller will be
summarized and sent to Purchaser by facsimile transmission to the attention of the Department of Drug Safety at the current facsimile number of (951) 493-5825, with an original sent on the same day by U.S. mail to Purchaser at 311 Bonnie
Circle, Corona, California 92880, Attention: Department of Drug Safety. Each product quality complaint report summarized by Purchaser and/or Seller shall include a description of the event, field sample availability, lot number availability and a
cross reference of such complaint in the sender’s files. At the end of each calendar month, Purchaser and/or Seller shall provide the other with a list of all of the product quality complaint reports received by said party for purposes of
conducting a monthly reconciliation of all such complaints. Purchaser and Seller shall notify each other of (i) any adverse drug experience or reaction reports, trend or any other reports or information indicating that any of the finished
Product hereunder have any toxicity, sensitivity reactions, or are otherwise alleged to cause illness or injury of any kind or are adulterated or misbranded, or (ii) any product complaints made by customers that will or could cause an FDA
“field alert” to be issued, within twenty-four (24) hours of becoming aware of any such difficulties, and shall thereafter reasonably cooperate with each other relative to any investigation or inquiry that may be initiated by the FDA
with respect thereto (which Seller shall have the right to direct and control). For purposes of 

  
 20 

 Execution Copy 

 
 
clarification, the parties acknowledge that the foregoing complaint handling procedures shall only apply to complaints which implicate the manufacturing, packaging, testing or storage of a
Product. 
 10.8 Labeling. The Purchaser shall have responsibility for all labeling graphics and the user
instructions, in the case where the Seller’s user instructions have been modified. The Seller, as holder of the NDA, has responsibility for any remaining, non-specified, labeling content. 

10.9 Inspections.  
 10.9.1 In the event Seller’s manufacturing, packaging, testing or storage facility producing Products hereunder is inspected by representatives of any federal agency in connection with Seller’s
manufacture of a Product, Seller shall notify Purchaser promptly upon learning of such inspection, and shall supply Purchaser with redacted copies of any correspondence or portions of correspondence which relate to such Product. Purchaser may send
representatives to such manufacturing, packaging, testing or storage facility and may participate in any portion of such inspection relating to such Product (and shall do so upon the request of Seller). In the event Seller receives any regulatory
letter or comments from any federal agency in connection with its manufacture of the Product requiring a response or action by Seller, including, but not limited to, receipt of a Form 483 (Inspectional Observations) or a “Warning Letter,”
Purchaser promptly will provide Seller with any data or information required by Seller in preparing any response relating to Seller’s manufacture of the Product, and will cooperate fully with Seller in preparing such response. 

10.9.2 In the event Purchaser is inspected or receives a regulatory letter or comments from any federal agency in
connection to the distribution of the Products, Purchaser shall notify Seller promptly upon learning of such inspection or receiving such documentation. Seller may participate in that portion of such inspection relating to such Product (and shall be
required to participate if requested by Purchaser). If Seller or Purchaser requests Seller to participate as described above, Seller and Purchaser shall mutually agree on the response with respect to such Product and Purchaser shall be responsible
for submitting any such responses to the regulatory authorities. Purchaser will provide Seller with all data or information reasonably required by Seller in preparing for any such inspection or any response relating to the Products. 

10.10 Cooperation. Seller shall provide reasonable assistance to Purchaser in its preparation and filing with appropriate
regulatory agencies (including both federal and state agencies related to reimbursement and health care insurance) of filings required for the marketing and distribution of Products in the Territory by Purchaser. Seller and Purchaser shall work
together in good faith to develop such necessary regulatory strategies which may be required for purposes of this Agreement. In addition, Seller shall provide to Purchaser copies (in electronic format if available) of those materials which Seller
currently uses to respond to inquiries regarding the Products from consumers and health care professionals. 

  
 21 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

SECTION 11 

FORCE MAJEURE 
 11.1 Force Majeure Events. If either party is prevented from performing any of its obligations hereunder (except for any financial payments due hereunder) due to any cause which is beyond
the non-performing party’s reasonable control, including fire, explosion, flood, or other acts of God; acts, regulations, or laws of any government; court injunction or other court order; war or civil commotion; strike, lock-out or labor
disturbances; or failure of public utilities or common carriers (a “Force Majeure Event”), such non-performing party shall not be liable for breach of this Agreement with respect to such non-performance to the extent any such
non-performance is due to a Force Majeure Event. Such non-performance will be excused for as long as such event shall be continuing (whichever occurs sooner), provided that the non-performing party gives immediate written notice to the other party
of the Force Majeure Event. Such non-performing party shall exercise all reasonable efforts to eliminate the Force Majeure Event and to resume performance of its affected obligations as soon as practicable. In the event such Force Majeure Event
continues unabated for a period of nine (9) months or longer, then the party which is not subject to such Force Majeure Event may terminate this Agreement on thirty (30) days prior written notice to the other party. 

SECTION 12 

INSURANCE 

12.1 Each party agrees to procure and maintain in full force and effect during the term of this Agreement, at its sole cost and expense
(i) Statutory Worker’s Compensation Insurance and Employer’s Liability Insurance and (ii) Products Liability and General Liability Insurance with a limit of not less than $[**] per occurrence and $[**] in the aggregate annually.
Upon written request, each party shall provide to the other party copies of a certificate of insurance of such insurance coverage. Either party may substitute a program of self-insurance for all or part of the third party insurance required
hereunder. 
 SECTION 13 
 CONFIDENTIALITY 
 13.1 As used herein, “Confidential Information”
shall include all confidential or proprietary information given to one party by the other party, or otherwise acquired by such party in its performance of this Agreement, relating to such other party or any of its

  
 22 

 Execution Copy 

 
 
Affiliates, including information regarding any of the products of such other party or any of its Affiliates, information regarding its advertising, distribution, marketing or strategic plans or
information regarding its costs, productivity or technological advances. Neither party shall use or disclose to Third Parties any Confidential Information of the other (except to comply with its obligations under this Agreement) and each party shall
insure that its and its Affiliates’ employees, officers, representatives and agents shall not use or disclose to Third Parties any Confidential Information and upon the termination of this Agreement shall return to the other or destroy all
Confidential Information in written form. Confidential Information shall not include information that (i) was already known to receiving party at the time of its receipt thereof or is independently developed by receiving party, as evidenced by
its written records, (ii) is disclosed to receiving party after its receipt thereof by a third party who, receiving party knows, has a right to make such disclosure without violating any obligation of confidentiality, (iii) is or becomes
part of the public domain through no fault of receiving party or (iv) is independently developed by a party. Except as provided herein, the terms of this Agreement (including, without limitation, the exhibits hereto) shall be maintained in
confidence by the parties hereto. The obligations of confidentiality set out above shall survive termination or expiration of this Agreement for a period of three (3) years. 

SECTION 14 

PUBLIC ANNOUNCEMENTS; ETC. 
 14.1 The parties hereto covenant and agree that, except as provided for herein below, each will not from and after the date hereof make, issue or release any public announcement, press release, statement
or acknowledgment of the existence of, or reveal publicly the terms, conditions and status of, the transactions contemplated herein, without the prior written consent of the other party as to the content and time of release of and the media in which
such statement or announcement is to be made; provided, however, that in the case of announcements, statements, acknowledgments or revelations which either party is required by law to make, issue or release, the making, issuing or
releasing of any such announcement, statement, acknowledgment or revelation by the party so required to do so by law shall not constitute a breach of this Agreement if such party shall have given, to the extent reasonably possible, not less than
five (5) business days prior notice to the other party (except in the case of media inquiries (which shall require a lesser amount of time), if such party shall have used its reasonable best efforts to notify the other party), and shall have
attempted, to the extent reasonably possible, to clear such announcement, statement, acknowledgment or revelation with the other party. Notwithstanding the foregoing, the parties acknowledge that there may be a need to engage in daily or frequent
contact with government agencies and/or other Third Parties which may make inquiries with respect to this Agreement after its initial public disclosure. This Section 14 is not intended to prohibit responding to such inquiries so long as any
such responses shall remain consistent with the statements and other public relations material which has been approved by the parties in accordance with this Section 14, and the maximum advanced notice possible is provided with respect to media
inquiries (if less than the previously outlined 5-day notification period). To the extent reasonably possible, the parties shall coordinate with each other on any such subsequent responses. 

  
 23 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

14.2 The parties acknowledge that as of the date hereof, they have agreed upon the text of press releases with respect to this Agreement
in the forms attached as Exhibit E. 
 14.3 Purchaser shall not use the name of Seller or any of its Affiliates for advertising,
promotional or other purposes without the prior written consent of Seller. In furtherance of the foregoing, Purchaser shall not originate any publicity or other announcement, written or oral, whether to the public, the press, the trade,
Purchaser’s or Seller’s customers or otherwise, relating to this Agreement or the existence of an arrangement between the parties, without the prior written approval of Seller, except as otherwise permitted under the terms of this
Agreement. Any breach of the terms of this Agreement by Purchaser shall be deemed a material breach of this Agreement. 

SECTION 15 

REPRESENTATIONS AND WARRANTIES 
 15.1 Product Warranties. Seller represents and warrants to Purchaser that all Products supplied in connection with this Agreement shall be manufactured and provided in accordance and
conformity with the Specifications. Seller represents and warrants that it shall comply with all present and future statutes, laws, ordinances and regulations relating to the manufacture and supply of the Product being provided hereunder, including,
without limitation, those enforced by the FDA (including compliance with good manufacturing practices) and the DEA. Seller further represents and warrants that, to its knowledge and as of the date of this Agreement, the manufacture of Products by
Seller does not infringe any patent of any third party. SELLER MAKES NO OTHER REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY AS TO MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR
ANY OTHER MATTER WITH RESPECT TO THE PRODUCT. 
 15.2 LIMITATION ON LIABILITY OF SELLER. IN THE EVENT THAT
(I) ANY PRODUCT DOES NOT MEET THE SPECIFICATIONS THEREFOR, OR (II) SELLER HAS OTHERWISE BREACHED THIS AGREEMENT, THEN THE LIABILITY OF SELLER HEREUNDER TO PURCHASER (INCLUDING, BUT NOT LIMITED TO, CLAIMS OR COSTS RELATED TO PRODUCT LIABILITY
CLAIMS OR OTHERWISE), SHALL NOT, (X) WITH RESPECT TO THOSE CLAIMS BASED UPON THE PRECEDING CLAUSE (I), EXCEED $[**] MILLION PER OCCURRENCE AND $[**] MILLION IN THE AGGREGATE ANNUALLY AND (Y) WITH RESPECT TO THOSE CLAIMS BASED UPON THE
PRECEDING CLAUSE (II), EXCEED $[**] MILLION (EXCEPT AS PROVIDED IN SECTION 15.3(B)). 

  
 24 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

15.3 LIMITATION ON LIABILITY OF PARTIES.  
 (A) EXCEPT AS EXPRESSLY PROVIDED IN SECTION 15.3(B), IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, INCIDENTAL,
CONSEQUENTIAL OR PUNITIVE DAMAGES OR FOR ANY LOSS OF PROFITS OR REVENUES ARISING OUT OF OR RESULTING FROM ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR
OTHERWISE. 
 (B) THE LIMITATIONS AND DISCLAIMER SET FORTH IN (I) THE PRECEDING CLAUSE (A) FOR LOSS OF PROFITS AND
(II) SECTION 15.2(Y) (AS IT RELATES TO THE $[**] MILLION AMOUNT), SHALL NOT APPLY TO A CLAIM BY PURCHASER AGAINST SELLER FOR DAMAGES RESULTING FROM AN INTENTIONAL BREACH OF THIS AGREEMENT BY SELLER OF ITS OBLIGATION TO SUPPLY PRODUCT TO
PURCHASER IN ACCORDANCE WITH THE TERMS OF THIS AGREEMENT ONLY IF ALL OF THE FOLLOWING CRITERIA ARE SATISFIED BY SUCH CLAIM: 
  

	 	(V)	THE CLAIM RELATES TO A TIME PERIOD DURING WHICH SELLER HAD SUFFICIENT QUANTITIES OF THE PRODUCTS TO PROVIDE TO PURCHASER AS SET FORTH IN THIS AGREEMENT (UNLESS THE
SELLER HAS FAILED TO MAINTAIN SUFFICIENT QUANTITIES OF PRODUCTS FOR THE PURPOSE OF WITHHOLDING IT FROM PURCHASER), AND 

  

	 	(W)	DURING SUCH TIME PERIOD, SELLER SOLD THE NDA PRODUCT IN THE TERRITORY, AND 

 

	 	(X)	DURING SUCH TIME PERIOD, SELLER INTENTIONALLY BREACHED THIS AGREEMENT BY WITHHOLDING THE PRODUCTS FROM PURCHASER FOR A PERIOD OF AT LEAST THREE (3) MONTHS FOR THE
PURPOSE OF SELLING MORE OF THE NDA PRODUCT IN THE TERRITORY THAN SELLER WOULD HAVE OTHERWISE SOLD IN LIEU OF SUPPLYING THE PRODUCTS TO PURCHASER IN ACCORDANCE WITH THIS AGREEMENT, AND 

 

	 	(Y)	DURING SUCH TIME PERIOD, A FORCE MAJEURE EVENT AS DESCRIBED IN SECTION 11.1 DID NOT APPLY, AND 

 

	 	(Z)	DURING SUCH TIME PERIOD, PURCHASER WAS NOT IN BREACH OF THIS AGREEMENT. 

  
 25 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

PROVIDED, HOWEVER, IN NO EVENT SHALL SELLER BE LIABLE TO PURCHASER FOR DAMAGES IN EXCESS OF $[**] (THE “TOTAL CAP”) IN THE AGGREGATE. PURCHASER
AGREES TO SUBMIT ANY CLAIM FOR DAMAGES PURSUANT TO THIS SECTION 15.3 FOR RESOLUTION BY ARBITRATION AS SET FORTH IN SECTION 17.2. 
 (C) WITH RESPECT TO ANY CLAIM FOR DAMAGES AS PROVIDED IN SECTION 15.3(B), PURCHASER ACKNOWLEDGES AND AGREES TO THE FOLLOWING: 

 

	 	(I)	THAT THE TOTAL CAP SET FORTH ABOVE IS NOT INTENDED TO BE AND SHALL NOT BE DEEMED TO BE A LIQUIDATED DAMAGES AMOUNT; 

 

	 	(II)	THAT THE ARBITRATION PANEL SET FORTH IN SECTION 17.2 SHALL DETERMINE WHETHER ALL OF THE CRITERIA SET FORTH IN SECTION 15.3(B) HAVE BEEN MET AND WHETHER PURCHASER IS
ENTITLED TO DAMAGES, INCLUDING LOSS OF PROFITS, PURSUANT TO SECTION 15.3(B) IN ACCORDANCE WITH LAW; 

  

	 	(III)	THAT PURCHASER MUST ESTABLISH THE ACTUAL AMOUNT OF ITS DAMAGES IN ACCORDANCE WITH APPLICABLE LAW, AND SHALL NOT BE ENTITLED TO RECOVER DAMAGES TO THE EXTENT PURCHASER
IS ABLE TO MITIGATE ITS DAMAGES, INCLUDING, WITHOUT LIMTATION, BY SECURING A COVER SOURCE FOR THE PRODUCTS; AND 

  

	 	(IV)	THAT SECTIONS 15.2(II), 15.2(Y) AND THE PROVISO AT THE END OF 15.3(B) SHALL BE REDACTED AND NOT OTHERWISE DISCLOSED IN ANY ARBITRATION PROCEEDING AND SHALL BE APPLIED
BY THE PARTIES IF AND AFTER A FINAL DAMAGE AMOUNT IS AWARDED. 

 (D) FOR THE AVOIDANCE OF DOUBT, PURCHASER AGREES
IT IS NOT ENTITLED TO CLAIM DAMAGES IN EXCESS OF THE LIMITS SET FORTH IN SECTION 15.2 OR LOSS OF PROFITS FOR ANY PRODUCT THAT SELLER HAS SUPPLIED THAT DOES NOT MEET THE SPECIFICATIONS THEREFOR. 

15.4 Execution and Performance of Agreement. Seller and Purchaser each represents to the other that it has full right,
power and authority to enter into and perform its obligations under this Agreement. Seller and Purchaser each further represents and warrants to the other that the performance of its obligations under this Agreement will not result in a violation or
breach of, and will not conflict with or constitute a default under any agreement, contract, commitment or obligation to which such party or any of its Affiliates is a party or by which it is bound. 

  
 26 

 Execution Copy 

 
 15.5 Distribution and Sale of Product. Seller
shall not be responsible in any manner whatsoever for the proper storage (after delivery to Purchaser), distribution or sale of the Product by Purchaser. Purchaser agrees that all such distribution, marketing and sales activities shall be done in
accordance with all applicable laws, rules and regulations. EXCEPT FOR SELLER’S LIMITED REPRESENTATIONS SET FORTH IN THIS SECTION 15 (AND SUBJECT TO SELLER’S LIMITATIONS ON LIABILITY SET FORTH IN THIS SECTION 15), AND SUBJECT TO ANY
SELLER INDEMNIFICATION OBLIGATION UNDER SECTION 16, PURCHASER SHALL BE SOLELY RESPONSIBLE FOR ANY AND ALL LIABILITIES, CLAIMS, DAMAGES, COSTS, CHARGES, JUDGMENTS AND EXPENSES WHICH ARISE FROM OR RELATE TO PURCHASER’S MARKETING, DISTRIBUTION AND
SALE OF THE PRODUCTS BEING SUPPLIED HEREUNDER.  
 SECTION 16 

INDEMNIFICATION 
 16.1 Indemnification by Seller. Subject to the limitations set forth in Section 15 above and excluding those matters for which Purchaser is obligated to indemnify Seller pursuant to
this Agreement, Seller shall indemnify and hold harmless Purchaser (and its Affiliates) from and against any and all damages, liabilities, claims, costs, charges, judgments and expenses (including reasonable attorneys’ fees) (collectively
“Damages”) that may be sustained, suffered or incurred by Purchaser (or its Affiliates), arising from or by reason of (i) the breach by Seller of any warranty, representation, covenant or agreement made by Seller in this Agreement or
(ii) the intentional misconduct of Seller or, to the extent related to any action of an Affiliate of Seller in connection with this Agreement, the Affiliates of Seller. 
 16.2 Indemnification by Purchaser. Purchaser shall indemnify and hold harmless Seller (and its Affiliates) from and against any and all Damages, that may be sustained, suffered or incurred
by Seller (or its Affiliates) arising (i) directly from or by reason of the breach by Purchaser of any warranty, representation, covenant or agreement made by Purchaser in this Agreement; (ii) directly or indirectly from the distribution,
marketing, or sale of the Products by Purchaser, its Affiliates and its Wholesaler Affiliates (including, but not limited to, any product liability claims with respect to the Products, or any claims made with respect to Purchaser’s Trademarks
or other intellectual property or materials used by Purchaser in connection with the Products); or (iii) the intentional misconduct of Purchaser or, to the extent related to any action of an Affiliate of Purchaser and Wholesaler Affiliate in
connection with this Agreement, the Affiliates of Purchaser and its Wholesaler Affiliate, but excluding in each case above those matters for which Seller is obligated to indemnify Purchaser pursuant to Section 16.1. 

  
 27 

 Execution Copy 

 
 16.3 Claims. Each indemnified party agrees to
give the indemnifying party prompt written notice of any matter upon which such indemnified party intends to base a claim for indemnification (an “Indemnity Claim”) under this Section 16. The indemnifying party shall have the right to
participate jointly with the indemnified party in the indemnified party’s defense, settlement or other disposition of any Indemnity Claim. With respect to any Indemnity Claim relating solely to the payment of money damages and which could not
result in the indemnified party’s becoming subject to injunctive or other equitable relief or otherwise adversely affect the business of the indemnified party in any manner, and as to which the indemnifying party shall have acknowledged in
writing the obligation to indemnify the indemnified party hereunder, the indemnifying party shall have the sole right to defend, settle or otherwise dispose of such Indemnity Claim, on such terms as the indemnifying party, in its sole discretion,
shall deem appropriate; provided that the indemnifying party shall provide reasonable evidence of its ability to pay any damages claimed and with respect to any such settlement shall obtain the written release of the indemnified party from the
Indemnity Claim. The indemnifying party shall obtain the written consent of the indemnified party prior to ceasing to defend, settling or otherwise disposing of any Indemnity Claim if as a result thereof the indemnified party would become subject to
injunctive or other equitable relief or the business of the indemnified party would be adversely affected in any manner. 

SECTION 17 

DISPUTE RESOLUTION 
 17.1 Executive Resolution. If any dispute arises between the parties relating to the interpretation, breach or performance of this Agreement or the grounds for the termination thereof, the
parties agree that before submitting such dispute to arbitration as set forth in Section 17.2 below, the Presidents (or equivalent level) of each party shall, for a period of thirty (30) days after such dispute is formally submitted to
either of such Presidents in writing, attempt in good faith to negotiate a resolution of the dispute. The foregoing shall not be interpreted to preclude either party from seeking and obtaining from the appropriate court provisional remedies such as
attachment, preliminary injunction, replevin, etc. to avoid irreparable harm, maintain the status quo, or preserve the subject matter of the dispute. 
 17.2 Arbitration. 
 17.2.1 Any dispute, claim or controversy arising
from or related in any way to this Agreement or the interpretation, application, breach, termination or validity thereof, including any claim of inducement of this Agreement by fraud or otherwise, will be submitted for resolution by arbitration
pursuant to the rules then pertaining of the CPR Institute for Dispute Resolution for Non-Administered Arbitration (available at www.cpradr.org/arb-rules.htm), or successor (“CPR”), except where those rules conflict with these provisions,
in which case these provisions control. The arbitration will be held in the City of New York, Borough of New York, New York. 

  
 28 

 Execution Copy 

 
 17.2.2 The panel shall consist of three arbitrators chosen
from the CPR Panels of Distinguished Neutrals (or, by agreement, from another provider of arbitrators) each of whom is a lawyer with at least 15 years experience with a law firm or corporate law department of over 25 lawyers or who was a judge of a
court of general jurisdiction. In the event the aggregate damages sought by the claimant are stated to be less than $5 million, and the aggregate damages sought by the counterclaimant are stated to be less than $5 million, and neither side seeks
equitable relief, then a single arbitrator shall be chosen, having the same qualifications and experience specified above. Each arbitrator shall be neutral, independent, disinterested, impartial and shall abide by The CPR-Georgetown Commission
Proposed Model Rule for the Lawyer as Neutral available at www.cpradr.org/cpr-george.html. 
 17.2.3 The parties agree to
cooperate (1) to attempt to select the arbitrator(s) by agreement within 45 days of initiation of the arbitration, including jointly interviewing the final candidates, (2) to meet with the arbitrator(s) within 45 days of selection and
(3) to agree at that meeting or before upon procedures for discovery and as to the conduct of the hearing which will result in the hearing being concluded within no more than nine (9) months after selection of the arbitrator(s) and in the
award being rendered within 60 days of the conclusion of the hearings, or of any post-hearing briefing, which briefing will be completed by both sides within 45 days after the conclusion of the hearings. 

17.2.4 In the event the parties cannot agree upon selection of the arbitrator(s), the CPR will select arbitrator(s) as follows: CPR shall
provide the parties with a list of no less than 25 proposed arbitrators (15 if a single arbitrator is to be selected) having the credentials referenced above. Within 25 days of receiving such list, the parties shall rank at least 65% of the proposed
arbitrators on the initial CPR list, after exercising cause challenges. The parties may then interview the five candidates (three if a single arbitrator is to be selected) with the highest combined rankings for no more than one hour each and,
following the interviews, may exercise one peremptory challenge each. The panel will consist of the remaining three candidates (or one, if one arbitrator is to be selected) with the highest combined rankings. In the event these procedures fail to
result in selection of the required number of arbitrators, CPR shall select the appropriate number of arbitrators from among the members of the various CPR Panels of Distinguished Neutrals, allowing each side challenges for cause and three
peremptory challenges each. 
 17.2.5 In the event the parties cannot agree upon procedures for discovery and conduct of the
hearing meeting in the schedule set forth in Section 17.2.3 above, then the arbitrator(s) shall set dates for the hearing, any post-hearing briefing, and the issuance of the award in accord with the schedule set out in Section 17.2.3. The
arbitrator(s) shall provide for discovery according to those time limits, giving recognition to the understanding of the parties that they contemplate reasonable discovery, including document demands and depositions, but that such discovery be
limited so that the schedule set out in Section 17.2.3 may be met without difficulty. In no event will the arbitrator(s), absent agreement of the parties, 

  
 29 

 Execution Copy 

 
 
allow more than a total of ten days for the hearing or permit either side to obtain more than a total of 40 hours of deposition testimony from all witnesses, including both fact and expert
witnesses, or serve more than 20 individual requests for documents, including subparts, or 20 individual requests for admission or interrogatories, including subparts. Multiple hearing days will be scheduled consecutively to the greatest extent
possible. 
 17.2.6 The arbitrator(s) must render their award by application of the substantive law of the State of New Jersey
and are not free to apply “amiable compositeur” or “natural justice and equity.” The arbitrator(s) shall render a written opinion setting forth findings of fact and conclusions of law with the reasons therefor stated. A
transcript of the evidence adduced at the hearing shall be made and shall, upon request, be made available to either party. The arbitrator(s) shall have power to exclude evidence on grounds of hearsay, prejudice beyond its probative value,
redundancy, or irrelevance and no award shall be overturned by reason of such ruling on evidence. To the extent possible, the arbitration hearings and award will be maintained in confidence. 

17.2.7 In the event the panel’s award exceeds $5 million in monetary damages or includes or consists of equitable relief, or rejects
a claim in excess of that amount or for that relief, then the losing party may obtain review of the arbitrators’ award or decision by a single appellate arbitrator (the “Appeal Arbitrator”) selected from the CPR Panels of
Distinguished Neutrals by agreement or, failing agreement within seven working days, pursuant to the selection procedures specified in Section 17.2.4 above. If CPR cannot provide such services, the parties will together select another provider
of arbitration services that can. No Appeal Arbitrator shall be selected unless he or she can commit to rendering a decision within forty-five days following oral argument as provided in this paragraph. Any such review must be initiated within
thirty (30) days following the rendering of the award referenced in Section 17.2.6 above. 
 17.2.8 The Appeal
Arbitrator will make the same review of the arbitration panel’s ruling and its bases that the U.S. Court of Appeals of the Circuit where the arbitration hearings are held would make of findings of fact and conclusions of law rendered by a
district court after a bench trial and then modify, vacate or affirm the arbitration panel’s award or decision accordingly, or remand to the panel for further proceedings. The Appeal Arbitrator will consider only the arbitration panel’s
findings of fact and conclusions of law, pertinent portions of the hearing transcript and evidentiary record as submitted by the parties, opening and reply briefs of the party pursuing the review, and the answering brief of the opposing party, plus
a total of no more than four (4) hours of oral argument evenly divided between the parties. The party seeking review must submit its opening brief and any reply brief within seventy-five (75) and one hundred thirty (130) days,
respectively, following the date of the award under review, whereas the opposing party must submit its responsive brief within one hundred ten (110) days of that date. Oral argument shall take place within five (5) months after the date of
the award under review, and the Appeal 

  
 30 

 Execution Copy 

 
 
Arbitrator shall render a decision within forty-five (45) days following oral argument. That decision will be final and not subject to further review, except pursuant to the Federal
Arbitration Act. 
 17.2.9 The parties consent to the jurisdiction of the Federal District Court for the district in which the
arbitration is held for the enforcement of these provisions and the entry of judgment on any award rendered hereunder (including after review by the Appeal Arbitrator where such an appeal is pursued). Should such court for any reason lack
jurisdiction, any court with jurisdiction shall act in the same fashion. 
 17.2.10 Each party has the right before or, if the
arbitrator(s) cannot hear the matter within an acceptable period, during the arbitration to seek and obtain from the appropriate court provisional remedies such as attachment, preliminary injunction, replevin, etc. to avoid irreparable harm,
maintain the status quo, or preserve the subject matter of the arbitration. 
 17.2.11 EACH PARTY HERETO WAIVES
ITS RIGHT TO TRIAL OF ANY ISSUE BY JURY. 
 17.2.12 EACH PARTY HERETO WAIVES ANY CLAIM TO PUNITIVE, EXEMPLARY OR
MULTIPLIED DAMAGES FROM THE OTHER. 
 17.2.13 EXCEPT TO THE EXTENT LOSS OF PROFITS AS PROVIDED IN SECTION 15.3(B) ARE
DEEMED CONSEQUENTIAL DAMAGES IN ACCORDANCE WITH APPLICABLE LAW, EACH PARTY HERETO WAIVES ANY CLAIM OF CONSEQUENTIAL DAMAGES FROM THE OTHER. 
 17.2.14 EACH PARTY HERETO WAIVES ANY CLAIM FOR ATTORNEYS’ FEES AND COSTS AND PREJUDGMENT INTEREST FROM THE OTHER. 
 17.2.15 EXCEPT AS OTHERWISE PROVIDED IN SECTION 15.3(B), EACH PARTY HERETO WAIVES ANY CLAIM FOR LOSS OF PROFITS FROM THE OTHER. 

SECTION 18 

MISCELLANEOUS 
 18.1 Relationship of the Parties. The relationship of Purchaser and Seller established by this Agreement is that of independent contractors, and nothing contained herein shall be construed
to (i) give either party any right or authority to create or assume any obligation of any kind on behalf of the other or (ii) constitute the parties as partners, joint venturers, co-owners or otherwise as participants in a joint or common
undertaking. 

  
 31 

 Execution Copy 

 
 18.2 Third Party Rights. Nothing in this
Agreement shall be deemed to create any third party beneficiary rights in or on behalf of any other person. 
 18.3 Entire
Agreement. It is the mutual desire and intent of the parties to provide certainty as to their respective future rights and remedies against each other by defining the extent of their mutual undertakings as provided herein. The parties have,
in this Agreement (including the Exhibits hereto), incorporated all representations, warranties, covenants, commitments and understandings on which they have relied in entering into this Agreement, and, except as provided for herein, neither party
makes any covenant or other commitment to the other concerning its future action. Accordingly, this Agreement and the Exhibits hereto (i) constitute the entire agreement and understanding between the parties with respect to the subject matter
hereof and there are no promises, representations, conditions, provisions or terms related thereto other than those set forth in this Agreement and (ii) supersedes all previous understandings, agreements and representations between the parties,
written or oral. No modification, change or amendment to this Agreement shall be effective unless in writing signed by each of the parties hereto. 
 18.4 Headings. The Article and Section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning and interpretation of this Agreement.

 18.5 Notices. All notices and other communications hereunder shall be in writing. All notices hereunder of an
Indemnity Claim, a Force Majeure Event, default or breach hereunder, or, if applicable, termination or renewal of the term hereof, or any other notice of any event or development material to this Agreement taken as a whole, shall be delivered
personally, or sent by national overnight delivery service or postage pre-paid registered or certified U.S. mail, and shall be deemed given: when delivered, if by personal delivery or overnight delivery service; or if so sent by U.S. mail, five
business days after deposit in the mail, and shall be addressed: 
 If to Seller: 

Watson Laboratories, Inc. 
 360 Mount Kemble Avenue 
 Morristown, NJ, 07962 

Attention: President and Chief Operating Officer 
 With a copy to: 
 Watson Pharmaceuticals, Inc. 

311 Bonnie Circle 

Corona, CA 92880-2882 
 Attention: General Counsel 

  
 32 

 Execution Copy 

 
 If to Seller: 

Ortho-McNeil-Janssen Pharmaceuticals, Inc. 
 1125 Trenton-Harbourton Rd 
 Titusville, New Jersey 08560 

Attention: President 
 With a copy to: 
 Johnson & Johnson 

Office of General Counsel 
 One Johnson & Johnson Plaza 
 New Brunswick, NJ 08933 

Attention: General Counsel 
 or to such other place as either party may designate by written notice to the other in accordance with the terms hereof. 
 18.6 Failure to Exercise. The failure of either party to enforce at any time for any period any provision hereof shall not be construed to be a waiver of such provision or of the right of
such party thereafter to enforce each such provision, nor shall any single or partial exercise of any right or remedy hereunder preclude any other or further exercise thereof or the exercise of any other right or remedy. Remedies provided herein are
cumulative and not exclusive of any remedies provided at law. 
 18.7 Assignment. This Agreement may not be
assigned by either party without the prior written consent of the other, except that (i) Seller may assign its rights and/or obligations hereunder to any of its Affiliates, to a successor to all of its business, or to a successor to that
portion of its business which relates to the manufacturing of the Product and (ii) Purchaser may assign its rights and/or obligations hereunder to any of its Affiliates. For purposes of this Section 18.7, the term “assignment”
shall include a Change in Control of Purchaser. Subject to the foregoing, this Agreement shall bind and inure to the benefit of the parties hereto and their respective successors and assigns. Notwithstanding anything to the contrary and for the
avoidance of doubt, nothing in this Agreement shall prevent Seller from receiving Products from a third party and providing such Products to Purchaser. 
 18.8 Severability. In the event that any one or more of the provisions (or any part thereof) contained in this Agreement or in any other instrument referred to herein, shall, for any reason,
be held to be invalid, illegal or unenforceable in any respect pursuant to a final, non-appealable decision in accordance with the dispute resolution provisions set forth in Section 17, then to the maximum extent permitted by law, such
invalidity, illegality or unenforceability shall not affect any other provision of this Agreement or any other such instrument. Any term or provision of this Agreement which is so held to be invalid, illegal or unenforceable in any jurisdiction
shall, to the 

  
 33 

 Execution Copy 

 
 
extent the economic benefits conferred by this Agreement to both parties remain substantially unimpaired, not affect the validity, legality or enforceability of any of the terms or provisions of
this Agreement in any other jurisdiction. 
 18.9 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 18.10 Expenses. Each party shall pay all of its own fees and expenses (including all legal, accounting and other advisory fees) incurred in connection with the negotiation and execution of
this Agreement and the arrangements contemplated hereby. 
 18.11 MMA Filing. Within ten (10) business days
following the date of this Agreement, each party shall file or cause to be filed with the FTC and the Antitrust Division of the U.S. Department of Justice (“DOJ”) this Agreement and any notifications required to be filed pursuant to any
applicable law. The parties shall use all commercially reasonable efforts and coordinate to make such filings promptly and to respond promptly to any requests for additional information made by either of such agencies. Each party reserves the right
to communicate with the FTC or DOJ regarding such filings and it believes appropriate. Each party shall keep the other reasonably informed of such communications and shall not disclose the Confidential Information of the other party without such
other party’s written consent (not to be unreasonably withheld, delayed or conditioned). 
 18.12 Survival.
Sections 3.5, 7.6, 13, 14, 15, 16, 17 and 18 shall survive the termination of this Agreement in accordance with the respective terms thereof. 
 [Signature Page Follows] 

  
 34 

 Execution Copy 

 
 IN WITNESS WHEREOF, the parties hereto have caused
this Agreement to be executed by their duly authorized respective representatives as of the day and year first above written. 
  

			
	WATSON LABORATORIES, INC.
		
	 By:
	 	 /s/ R. Todd Joyce

	 Name: R. Todd Joyce

	 Title: Senior Vice President & Chief Financial Officer

 ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. 

 

			
	 By:
	 	 /s/ Denice M. Torres

	 Name: Denice M. Torres

	 Title: Vice President and General Manager, CNS

  
 35 

 Execution Copy 

 
 LIST OF EXHIBITS 

Product 
 Purchase Prices 

Initial Order 
 Production Capacity or Raw
Material Shortage Allocation Press Release 

  
 36 

 Execution Copy 

 
 EXHIBIT A 

Products 
 18 mg
dosage in 100 count bottles 
 27 mg dosage in 100 count bottles 
 36 mg dosage in 100 count bottles 
 54 mg dosage in 100 count bottles 

  
 37 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

EXHIBIT B 

Purchase Prices 
  

					
	 Quarterly Period
	  	Purchase Price as a Percent of
Purchaser Net Sales	 
	 Start Date - June 30, 2011
	  	 	[	**]% 
	 July 1, 2011 - September 30, 2011
	  	 	[	**]% 
	 October 1, 2011 - December 31, 2011
	  	 	[	**]% 
	 January 1, 2012 - March 31, 2012
	  	 	[	**]% 
	 April 1, 2012 until the end of the term of the Agreement
	  	 	[	**]% 

 Notwithstanding the foregoing, the purchase price would be reduced to [**] percent of Watson’s Net Sales during any
period between the Start Date and March 31, 2012 when a third party AB-rated version of the NDA Product is available for sale in the Territory. Further, the purchase price would be reduced to [**] percent of Watson’s Net Sales during any
period between July 1, 2012 and December 31, 2014 when a third party AB-rated version of the NDA Product is available for sale in the Territory. 
 Minimum Amount - All Prices are for Bottles of 100 
 18 mg - [$[**]] 

27 mg - [$[**]] 
 36 mg - [$[**]] 

54 mg - [$[**]] 

  
 38 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

EXHIBIT C 

Initial Order 

The parties acknowledge that the amount of Purchaser’s Initial Order will depend on whether Seller receives the additional Product raw material
quota allocation which Seller has requested from the DEA. In the event Seller receives the additional Product raw material allocation it requested from the DEA by November 15, 2010, Purchaser will thereafter place its initial Order for the amounts
of Products as set forth below under the column “Projected Deliveries with Incremental API Quota requested from DEA”. In the event Seller does not receive the additional Product raw material allocation it required from the DEA by November
15, 2010, Purchaser shall place its Initial Order for the amounts of Products as set forth below under the column “Projected Deliveries without Incremental API Quota requested from DEA”. 

 

									
	Strength	  	 Delivery
 Date    
	  	 Projected
 Deliveries
 without

Incremental

API Quota

requested

from DEA
	  	 Projected
 Deliveries
 with

Incremental

API Quota

requested

from DEA
	  	 
		  	15-Apr	  	 [**]
	  	 [**]
	  	
	 18mg
	  		  		  		  	
					
		  	1-May	  	 [**]
	  	 [**]
	  	
					
		  	1-Jun	  	 [**]
	  	 [**]
	  	
					
		  	1-Jul	  	[**]	  	 [**]
	  	
					
		  	1-Aug	  	[**]	  	 [**]
	  	
					
	 27mg
	  	15-Apr	  	 [**]
	  	 [**]
	  	

  
 39 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

									
					
		  	1-May	  	 [**]
	  	[**]	  	
					
		  	1-Jun	  	 [**]
	  	 [**]
	  	
					
		  	1-Jul	  	 [**]
	  	 [**]
	  	
					
		  	1-Aug	  	 [**]
	  	 [**]
	  	
					
	 36mg
	  	15-Apr	  	 [**]
	  	 [**]
	  	
					
		  	1-May	  	 [**]
	  	 [**]
	  	
					
		  	1-Jun	  	 [**]
	  	 [**]
	  	
					
		  	1-Jul	  	 [**]
	  	 [**]
	  	
					
		  	1-Aug	  	 [**]
	  	 [**]
	  	
					
	 54mg
	  	15-Apr	  	 [**]
	  	 [**]
	  	
					
		  	1-May	  	 [**]
	  	 [**]
	  	
					
		  	1-Jun	  	 [**]
	  	 [**]
	  	
					
		  	1- Jul	  	 [**]
	  	 [**]
	  	
					
		  	1-Aug	  	 [**]
	  	 [**]
	  	

  
 40 

 Confidential portions of this Exhibit marked as [**] have been omitted pursuant to a

 request for confidentiality and filed separately with the Securities and Exchange Commission. 

Execution Copy 
  

EXHIBIT D 

Production Capacity and Raw Material Shortage Allocations 
 Start Date – May 31, 2011:[**] Percent to Purchaser 
 June 1, 2011 –
June 30, 2011: [**] Percent to Purchaser 
 July 1, 2011 – July 31, 2011: [**] Percent to Purchaser 

August 1, 2011 – until the end of the term of the Agreement: [**] Percent to Purchaser 

  
 41 

 Execution Copy 

 
 EXHIBIT E 

Press Release 
 Draft 

  
 42 

 

 
  

							
	NEWS RELEASE	  		  	    DRAFT 10-27-10
				
		  		  	CONTACTS:	  	Investors:
		  		  		  	Patty Eisenhaur
		  		  		  	(973) 355-8141
				
		  		  		  	Media:
		  		  		  	Charlie Mayr
		  		  		  	(973) 355-8483

 Watson Signs Exclusive Agreement to Distribute Authorized Generic Concerta® 
 MORRISTOWN, NJ — October XX, 2010 — Watson Phamiaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with
Ortho-McNeil-Janssen Pharmaceuticals, Inc., to market the authorized generic version of Concerto®
(methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta’ on May 1, 2011. Concerta is used to treat attention deficit disorder (ADD) and attention deficit hyperactivity disorder
(ADHD). 
 Under the terms of the agreement, Ortho-McNeil-Janssen will manufacture and exclusively supply Watson with all dosage strengths of
the authorized generic product. Watson will market and distribute the product in the United States. Ortho-McNeil-Janssen will receive a share of the net sales from Watson’s sales of the product. The agreement runs until the end of 2014. During
the term of the agreement, Watson will be permitted to continue to pursue U.S. Food and Drug Administration approval of its abbreviated new drug application (ANDA) for a generic version of Concerta and will be permitted to launch its own ANDA
product at the conclusion of the exclusive supply agreement. Other terms of the agreement were not disclosed. 

 This agreement ensures that consumers will benefit from a quality, cost effective product beginning in May
2011, removing any uncertainty of when a generic product could be approved,” said Paul Bisaro, Watson’s President and CEO. 
 For the
12-months ending June 30, 2010, Concerte had sales of approximately $1.3 billion, according to IMS Health data. 

 About Watson Pharmaceuticals, Inc. 
 Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and
specialized branded pharmaceutical products focused on Urology and Women’s Health. Watson has operations in many of the world’s established and growing international markets. 
 For press release and other company information, visit Watson Pharmaceuticals’ Web site at http://www.watson.com. 
 Forward-Looking Statement 
 Statements contained in this press release that refer to non-historical
facts are forward-looking statements that reflect Watson’s current perspective of existing information as of the date of this release. It is important to note that Watson’s goals and expectations are not predictions of actual performance.
Actual results may differ materially from Watson’s current expectations depending upon a number of factors, risks and uncertainties affecting Watson’s business. These factors include, among others, the impact of competitive products and
pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to
Watson and its third party manufacturers’ facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such
other risks and uncertainties detailed in Watson’s periodic public filings with the Securities and Exchange Commission, including but not limited to Watson’s annual report on Form 10-K for the year ended December 31,2009 and
Watson’s quarterly report on Form 10-Q for the period ended June 30, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. 

Concerta®
 is a registered trademark of Ortho-McNeil-Janssen Pharmaceuticals, Inc. 

 Privileged and Confidential 
 Not for Distribution or External 
 Disclosure REVISED FINAL: November 1, 2010

 Contacts: 
  

					
	 Media
	  	 Investors
	  	 
	Kara Russell: (609) 730-3771	  	Louise Mehrotra: (732) 524-6491	  	
		  	Stan Panasewicz: (732) 524-2524	  	

 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Enters into Agreement for 

CONCERTA® Authorized Generic 
 Titusville,
NJ (November 2, 2010) — Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA® (methylphenidate HCI extended-release tablets). Watson will launch the authorized generic beginning May 1,
2011. 
 “The availability of an authorized generic version of CONCERTA that is both bioequivalent and clinically equivalent to the
complex, extended-release innovator compound is particularly important — and reassuring — for patients with ADHD and their families,” states Don Heald, Vice President Clinical Pharmacology, Neurosciences, Johnson & Johnson
Pharmaceutical Research & Development, L.L.C. “It is also important for healthcare professionals who may consider prescribing a generic product for this condition.” 

In 2004, the affiliate of OMJPI that marketed CONCERTA at that time filed a Citizen Petition requesting generic versions of CONCERTA
demonstrate a similar onset of efficacy and a similar duration of effect to the innovator product. The Citizen Petition, which remains under review by the Food and Drug Administration (FDA), is not impacted by this agreement. McNeil Pediatrics, a
division of OMJPI, will continue to market the branded CONCERTA® product. 

 Under the terms of the agreement, OMJPI will manufacture and exclusively supply Watson with the authorized
generic product, which will be available in 18mg, 27mg, 36mg, and 54mg formulations. Watson will market and distribute the product in the United States until the end of 2014. 
 CONCERTA is approved for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 17 and in adults 18 to 65, as part of a total treatment program that may include counseling
or other therapies. 

 IMPORTANT SAFETY INFORMATION 
 Talk to your healthcare professional for a proper diagnosis and treatment of ADHD. Only a healthcare professional can decide whether medication is right for you or your child. 

CONCERTA should not be taken by patients who have: allergies to methylphenidate or other ingredients in CONCERTA; significant anxiety, tension, or
agitation; glaucoma; tics, Tourette’s syndrome, or family history of Tourette’s syndrome; current or past use of monoamine oxidase inhibitor (MAGI); esophagus, stomach, or intestinal narrowing. Children under 6 years of age should not take
CONCERTA. 
 Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if you or your child has had problems with
alcohol or drugs; has had any heart problems, heart defects, high blood pressure, or a family history of these problems; has had depression, abnormal thoughts or visions, bipolar disorder, or seizure. Contact your healthcare professional immediately
if you or your child: develops abnormal thinking or hallucinations, abnormal or extreme moods and/or excessive activity; or if aggressive behavior or hostility develops or worsens while taking CONCERTA. Your child’s healthcare professional
should check height and weight often and may interrupt CONCERTA treatment if your child is not growing or gaining weight as expected. 

Stimulants may impair the ability of the patient to operate potentially hazardous machinery or vehicles. Caution should be used accordingly until you
are reasonably certain that CONCERTA does not adversely affect your ability to engage in such activities. 
 The most common adverse
reaction (>5%) reported in children and adolescents was upper abdominal pain. The most common adverse reactions (>10%) reported in adults were dry mouth, nausea, decreased appetite, headache, and insomnia. 

CONCERTA contains methylphenidate, a Schedule II controlled substance under the Controlled Substances Act. 

For full prescribing information, go to www.concerta.net. 
 Ortho-McNeil-Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, provides medicines for an array of health concerns. The company strives to provide innovative, high quality, safe
and effective treatments and continually seeks new opportunities to offer solutions for unmet health care needs. Ortho McNeil-Janssen Pharmaceuticals, Inc. is headquartered in Titusville, New Jersey. 

 McNeil Pediatrics’”, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.,
is committed to meeting the needs of children, adolescents, adults and healthcare professionals through the development of therapies specifically formulated for children, adolescents and adults. McNeil PediatricsTM is a leader in the treatment of ADHD and markets a leading medication prescribed in the United States for children,
adolescents and adults with ADHD. The company is headquartered in Titusville, N.J. 

 Execution Copy 

 
 CONCERTA and OROS’ are registered trademarks of ALZA Corporation.

 This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform
Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialise, actual results could vary materially from Ortho-McNeilJanssen
Pharmaceuticals, Inc. and/or Johnson & Johnson’s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate
fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and
trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10K for the fiscal year ended
January 3, 2010. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov,
v.,ww.Ini.com or on request from Johnson & Johnson. Neither Ortho-McNeilJanssen Pharmaceuticals, Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new
information or future events or developments. 

  
 50

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}]]